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ABSTRACT    
Over  100  million  women  worldwide  are  currently  on  progestin-­based  
hormonal  contraceptives.  Despite  having  immunomodulatory  and  repair  
properties,  their  effects  on  the  outcome  of  viral  diseases  outside  of  the  
reproductive  tract  have  not  been  evaluated.  I  hypothesized  that  treatment  of  
influenza  A  virus-­infected  female  mice  with  progesterone  or  a  synthetic  analog,  
levonorgestrel,  would  protect  them  against  severe  disease.  Female  mice  treated  
with  progestins  were  significantly  protected  against  infection  with  different  strains  
and  doses  of  influenza  A  virus  as  compared  to  females  treated  with  placebo.  This  
protection  was  not  caused  by  a  reduction  in  virus  titers,  but  rather  by  decreased  
pulmonary  inflammation  and  tissue  damage,  increased  proliferation,  and  
improved  pulmonary  function  during  infection.  Treatment  with  progesterone  
reduced  inflammation  and  promoted  repair  by  inducing  TGF-­b,  IL-­22,  and  
suppressive  CD39+  Th17  cells  along  with  the  production  of  amphiregulin.  
Amphiregulin  mediated  progesterone-­induced  repair  as  treatment  of  
progesterone-­depleted  mice  with  amphiregulin  restored  protection  whereas  
depletion  of  amphiregulin  in  progesterone-­treated  females  impaired  protection  
during  IAV  infection.  In  vitro,  progesterone  facilitated  the  repair  of  damaged  
respiratory  epithelial  cell  cultures  and  induced  amphiregulin  production.  To  
investigate  whether  adaptive  immune  responses  and  the  outcome  of  sequential  
influenza  A  virus  infection  were  affected  by  progestins,  mice  were  treated  with  
progestins,  infected  with  H1N1  virus,  and  challenged  with  either  a  drift  variant  or  
a  H3N2  virus.  Treatment  with  progestins  reduced  virus-­specific  antibody  titers  in  
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the  serum  and  bronchoalveolar  lavage  fluid.  Protection  following  infection  with  
the  drift  variant  virus  was  similar  among  all  groups  and  correlated  with  high  titers  
of  broadly  neutralizing  antibodies.  In  contrast,  mice  treated  with  progestins  
suffered  greater  mortality  following  a  heterologous  infection  which  was  
characterized  by  increased  immunopathology  and  decreased  virus-­specific  
memory  CD8+  T  cells.  These  studies  demonstrate  that  progestins  are  a  critical  
host  factor  mediating  protection  from  severe  influenza  A  virus  by  promoting  
tissue  repair  and  reducing  inflammation  but  can  also  make  females  more  
susceptible  to  secondary  challenge  with  a  heterologous  influenza  A  virus  by  
decreasing  memory  responses,  and  altering  antibody  responses.  This  suggests  
that  progestin-­based  contraceptives  may  play  complex,  multifaceted  roles  during  
influenza  A  virus  infection  and  vaccination.	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PKR   protein  kinase  R  
PR   progesterone  receptor  
PRKO   progesterone  receptor  knock  out  
PRRs   pathogen  recognition  receptors  
RIG-­I   retinoic  acid  inducible  gene-­1  
Rrs   respiratory  system  resistance  
SA   sialic  acid  
SIV   simian  immunodeficiency  virus  
STIs   sexually  transmitted  infections  
ssRNA   single  stranded  RNA  
TBI   traumatic  brain  injury  
TCID50   tissue  culture  infectious  dose  50  
TCM   T  central  memory  
Th   T  helper  
TLR   toll-­like  receptor  
TNF-­a   tumor  necrosis  factor  a  
TRAIL   TNF-­related  apoptosis-­inducing  ligand  
TRM   tissue  resident  memory  
TSLP   thymic  stromal  lymphopoietin  
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Introduction to progesterone  
Natural progesterone (P4) is produced by the corpus luteum during the menstrual cycle in 
non-pregnant females and its production is sustained at high levels by the placenta during 
pregnancy (1). Serum levels of P4 fluctuate during the menstrual cycle with a peak of 20ng/ml 
during the luteal phase and the nadir (<1ng/ml) during the follicular phase (2). During pregnancy, 
the production of P4 is maintained by the placenta with increases from 12-90ng/ml during first 
trimester and up to 300ng/ml during the third trimester of pregnancy (2). In the 1940s synthetic 
analogs of P4, termed progestins, were developed and in the 1960s these compounds began being 
used as hormonal contraceptives (3). Exogenous P4 and progestins are used therapeutically in 
oral contraceptives by over 20 million young adult women in the United States alone (4).  
Progestins and P4 can freely diffuse through the cell membrane and signal through the 
progesterone receptor (PR), located in cytoplasm, which when bound, translocates to the nucleus, 
and binds progesterone response elements to alter transcription and downstream signaling (5). 
Progesterone receptor signaling can also occur in a non-genomic signaling manner via the MAPK 
or PI3K/Akt pathway, for example, or through membrane-bound PRs that signal by either 
increasing cAMP or through the JNK pathway and bypass the classical PR pathway all together 
(6-9). Progesterone receptors have two isoforms, A and B, which are derived from the same gene 
(10). Progestins bind the PR with higher affinity than P4; with levonorgestrel (LNG), for 
example, binding the PR with a 300% affinity relative to P4 (11). These PR are present in a wide 
range of tissues, on a variety of different cell types, including immune cells such as natural killer 
(NK) cells, macrophages, dendritic cells (DCs), T cells and non-immune cells, such as epithelial 
cells, endothelial cells, and neuronal cells (12, 13). Progestins and P4 can also signal through 
other steroid receptors including the androgen, glucocorticoid, and mineralocorticoid receptors 
which, like all steroid receptors, are also present in the cytoplasm (14, 15). As each of these 
receptors are widely distributed throughout the body and can bind progestins and P4, the effects 
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of progestins and P4 are not limited to the reproductive tract but occur in the central nervous 
system, respiratory system, cardiovascular system, and in certain tumors (16, 17).  
Progesterone-based contraceptives 
As noted above, in addition to natural exposure during the menstrual cycle and 
pregnancy, women of reproductive ages can be exposed to P4 in the form of hormone-based 
contraceptives. The “pill” which was approved by the Food and Drug Agency (FDA) in 1960 is 
typically composed of a combination of progestins (Table 1.1) and estrogen, but many hormonal 
contraceptives, such as intrauterine devices, contain progestin only formulations (18). Progestins 
exert their reproductive effects by thickening the mucus, suppressing ovulation by altering the 
luteinizing hormone (LH) and follicle stimulating hormone (FSH) surges, and making the 
endometrium inhospitable for implantation (15, 19). Many different contraceptive formulations 
exist, with new generations of progestins being developed that have higher affinity to the PR 
thereby reducing the dose required to be efficacious as well as reducing potential side-effects 
(Table 1.1). These can be used in conjunction with estrogen in combined oral contraceptives 
(COCs), or alone in the form of implants, injections (usually with depot medroxyprogestone 
acetate (DMPA)), intrauterine devices, rings, or as emergency contraceptive (15). In the United 
States alone, 35% of adult women are currently using hormonal methods of contraception, and 
88% of all adult women in the United States have been exposed to progestins in some form of 
contraceptives (20). Male hormonal contraception is currently being research and the 
administration of progestin such as LNG and etonorgestrel can also decrease pituitary LH and 
FSH production and testicular testosterone production and spermatogenesis without affecting 
secondary sexual characteristics (21). 
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Table 1.1: List of commonly used progestins 
Progestin Uses (reproductive system) 
Progesterone (P4) POC, HRT, dysmenorrhea treatment, ART 
Norethindrone 
COC, POC, endometriosis treatment, dysmenorrhea 
treatment 
Depot medroxyprogesterone acetate 
(DMPA) 
Injectable contraceptive, HRT 
Levonorgestrel (LNG) COC, IUD, emergency contraception, implants 
Etonogestrel Vaginal ring, implants 
Drospirenone COC, HRT 
 
Key: POC = P4 only contraceptive, COC = combined oral contraceptives, IUD = intrauterine 
device, HRT = Hormonal replacement therapy, ART – assisted reproductive technology.  
Sources: (15, 22, 23)  
Progesterone-based therapies 
In addition to their use in birth control, P4 and progestins are also used in combination 
with estrogen in hormone replacement therapy (HRT) in perimenopausal women to prevent the 
proliferative effects of estrogen on endometrial cells, which can lead to cancer and increased bone 
density (24). The potential side-effects of progestin-containing HRT, including increased breast 
cancer risks and heart disease, raised concerns following the Women’s Health Initiative trial, but 
the study was conducted with medroxyprogesterone acetate (MPA), which can transactivate the 
androgen and glucocorticoid receptor and thus lead to increased undesired side-effects (25). 
Newer generations of progestins are now used to prevent these side-effects and reduce the risk of 
breast cancer (26).  
Progesterone-based oral contraceptives have also been used for their “off-label” 
beneficial effects on conditions such as acne, polycystic ovary syndrome, and dysmenorrhea (4, 
19). Progestins can also increase bone density and have been used to prevent osteoporosis (27, 
28). More recently, P4 was shown to have a neuroprotective role following injury in the central 
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nervous system by dampening inflammation and promoting repair of myelin fibers in the context 
of traumatic brain injury and multiple sclerosis (17, 29). As such, it is currently used in clinical 
trials for treatment of traumatic brain injury and strokes in both men and women (29-32).  
The Immunomodulatory Effects of Progesterone 
Progesterone and immune cells 
The presence of PR on a wide variety of immune cells, suggest that these cells might 
respond to P4 treatment and indeed, in vitro studies show that P4 can alter the immune 
environment in various tissues and cell culture systems by promoting an anti-inflammatory state 
(Table 1.2). Classical nuclear PR and membrane-bound PR are located in NK cells, 
macrophages, DCs, and T cells (12, 33-37).  
Progesterone generally inhibits inflammatory innate immune responses. In vitro studies 
show that P4 can modulate immune pathway signaling in innate immune cells such as 
macrophages and DCs and suppress their activation (38, 39). For example, when P4 is bound to 
its receptor, it can directly interfere with the transcription factor NF-kB through transrepression 
and inhibit gene transcription downstream of the NF-kB pathway, including cyclooxygenase-2 
(COX-2) to decrease inflammation (38, 40-42). In human primary myometrial cells, P4 inhibits 
the MAPK pathway and downstream COX-2 and IL-1b expression via the glucocorticoid 
receptor (43). Progesterone can also decrease inflammation by inhibiting the production of pro-
inflammatory cytokines (e.g., TNF-a, IFN-g, and IL-12) and increasing production of anti-
inflammatory cytokines, including IL-10 (33, 39, 44, 45). Treatment of endometrial stem cell 
cultures, isolated from female patients with endometriosis, with different progestins reduces the 
production of IL-6, MCP-1, and TNF-a mRNA (46). Additionally, exposure of these stem cell 
cultures to either TNF-a or IL-1b decreases intracellular expression of PRs (44). Not all studies 
demonstrate anti-inflammatory effects of P4. For example, when cytokines in women taking 
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DMPA (see Table 1.1) were measured in endocervical swabs, levels of MIP-1, IL-6, and IL-8 
were increased (47, 48). In addition to signaling through the PR, DMPA can signal through the 
androgen and glucocortoid receptors, which can result in effects that are different than P4 (25, 
47).  
 In rodent bone-marrow derived DCs (BMDCs), administration of either P4 or LNG 
downregulates the activation of the toll-like receptors (TLR) 3 and 4 and the production of IL-6, 
IL-12p40, TNF-a, and IL-1b as well as the expression of CD80 and CD86 following stimulation 
with TLR ligands (33, 39). When BMDCs are co-cultured with T cells, the presence of P4 
decreased T cell proliferation in response to LPS (33). Similarly, P4 treatment of the macrophage 
cell line RAW264.7 inhibits TLR3, TLR4, and TLR9 signaling in response to Poly I:C, LPS, or 
CpG DNA, respectively, and downstream IL-6 and nitric oxide production (41, 49). Treatment 
with P4 can also alter the phenotype of macrophages by inducing the expression of Fizz-1 and 
YM-1, two markers of alternatively activated macrophages, and decreasing the production of 
nitric oxide following LPS stimulation (50). In murine bone marrow-derived macrophages treated 
with LPS, P4 but not LNG decreases nitric oxide production and the ability to lyse Leishmania 
intracellular parasites (51). NK cells are susceptible to P4-induced cell death which can be 
blocked by treatment with the P4 antagonist, RU-486 (34). Eosinophil numbers in ovariectomized 
rats treated with P4 are increased as compared with ovariectomized rats (52). 
Progesterone also alters the distribution and activity of T cells. Treatment of T cells in 
vitro with P4 can skew naïve T cells  away from Th1 responses and towards a Th2 type response, 
with increased production of IL-4, IL-5 and IL-10 (45, 53, 54). In human monocyte-derived DCs, 
treatment with P4 induces a Th2 environment with increased concentrations of IL-10, IL-13, and 
IL-27 (45). In T cell lines, the addition of P4 to the culture media induces a Th2 environment, 
with greater secretion of IL-4 and IL-5 as compared with non-P4 treated cultures (53). Murine T 
cells cultured to differentiate into either Th1 or Th2 cells in the presence of P4, show a strong 
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bias towards Th2 with decreased IFN-g production and enhanced Th2 responses, including 
production of IL-4 (54). In vivo, presence of P4 induces a regulatory milieu by increasing the 
production of the anti-inflammatory and repair cytokine TGF-b in the endometrium (55, 56). 
During pregnancy, high levels of P4 can shift the immune response towards a CD4+ T regulatory 
(Treg) phenotype (57). In human cord blood cells, P4 induces the differentiation of Tregs and 
suppresses Th17 cells through the modulation of transcriptions factors such as STAT5 and 
STAT3 (58).  
In B cells, the effects of P4 treatment are less well characterized. In vitro studies with B 
cells and endometrial cell co-cultures from mice show that in the presence of P4, B cells have 
decreased expression of CD80 and CD86 and a limited ability to present antigen (59). B cell 
hybridomas treated with P4 show decreased cellular proliferation and antibody production (60). 
In murine splenic B cells, P4 treatment decreases activation-induced deaminase (AID) mRNA 
and the ability of these cells to undergo somatic hypermutation and class-switch recombination 
(61). In combination with estradiol, but not alone, P4 has the ability to suppress B cell 
lymphopoiesis in mice (62).  
Taken together, these data illustrate that P4 and related compounds can bind to PRs to 
decrease inflammation by acting on the expression of cellular receptors, intracellular signaling 
and cytokine production to induce an anti-inflammatory milieu in a broad range of tissues.   
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Table 1.2: The effects of progestins on immunity 
 
Key: P4= progesterone, MPA=medroxyprogesterone acetate, DNG=dienogest, 
NETA=noresthisterone acetate, H=human, M=mouse, P=primate, R=rat, TLR= toll-like receptor, 
COX-2=cyclooxygenase 2, iNOS= inducible nitric oxide synthase, NO=nitric oxide, 
AID=activation-induced cytidine deaminase. 
 
 
Immune Response Progestin Species Outcome References 
TLR activity P4, LNG H, M ê  TLR3,  ê  TLR4,  ê  TLR7,      
ê  TLR9 
(39, 41, 49, 
63) 
Type I IFNs P4, MPA H, R ê  IFN-β (33, 42, 64) 
NF-κB signaling 
pathway P4 H 
Pathway inhibited 
ê  COX-2       (38, 40, 43) 
Macrophages P4, LNG M ê  iNOS, ê  NO 
é  Fizz-1, é  Ym-1 (49-51) 
Dendritic cells P4 H, M, R 
ê  CD40, ê  CD80, ê  CD86 
ê  TNF-α, ê  IL-6, ê  IL-12,            
ê  IL-1b 
é  IL-10,é   IL-8 
é  CD11c 
(33, 39, 45, 
65) 
NK cells P4 H ê  IFN-γ 
é  Apoptosis (caspase-dependent) (34) 









ê  TNF-α, ê  IFN-γ, ê  IL-12,         
ê  IL-6 
(33, 41, 44, 




P4, MPA H, M, P 
é  IL-4, é  IL-5, é  TGF-β, é  Il-13,  
= IL-10 
(45, 53, 55, 
56, 58, 66) 
Chemokines P4 M ê  MIP-2, MCP-1 (67) 
CD4+ Th1 P4 M, R ê  Development (33, 54) 
CD4+ Th2 P4 H, M 
é  Development 
é  IL-4, é  IL-5, é  IL-13, é  IL-27 
ê  IFN-γ 
(45, 53, 54) 
Tregs P4 H, M é  Percentages  (57, 58) 
B cells P4 M 
ê  Expression CD80 and CD86 
ê  Proliferation 
ê  AID and class-switching 
ê  Antibody responses 
(59-61, 68) 
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Progesterone and non-infectious diseases  
The immuno-modulatory effects of P4 result in profound effects of P4 on the outcome of 
diverse diseases. In mice sensitized with ovalbumin to model asthma, MPA increases allergic 
airway inflammation with increased eosinophilia and IL-5 but has no effect on the levels of IgE 
(66). In a murine model of multiple sclerosis (i.e., experimental autoimmune encephalomyelitis; 
EAE), administration of P4 decreases disease severity by reducing the production of pro-
inflammatory cytokines, such as IL-1b and IL-17, limiting cellular infiltration into the central 
nervous system, and increasing IL-10 production (64, 67). In a mouse model of systemic lupus 
erythematosus, inducing glomerulonephritis, DMPA treatment reduces mortality and the levels 
Th1 autoantibodies leading to limited glomerular damage (69). In rats with spinal cord injuries, 
treatment with P4 attenuates the injury-induced expression of IL-1b, IL-6, TNF-a, iNOS, and 
COX-2 in the central nervous system and promotes proliferation of oligodendrocyte precursor 
cells in wild-type (WT) but not in PR knock out (PRKO) rats (70, 71). Progesterone treatment can 
reduce inflammation due to traumatic brain injury (TBI) in both adult and neonatal rats by 
reducing COX-2, prostanglandin E2, TNF-a, brain permeability, and edema (72, 73). Human 
clinical studies also show that administration of P4 to patients with acute severe TBI improves 
neurological outcomes (32). When tested in Phase 3 clinical trials, P4 treatment failed to 
reproduce these findings but it has been suggested this may be due to suboptimal dosage and 
treatment duration along with the complexity of TBI pathophysiology and Phase 2B clinical trials 
are currently underway (31, 74, 75). In addition to studies in TBI models, the role of P4 in 
cerebral ischemia has been thoroughly studied, primarily in male rats, but also to a lesser extent in 
female rats as well as aged animals. Animals administered P4  show improved motor functions as 
well as decreased infarct volume and neuronal loss, with P4 upregulating VEGF and MMP9 and 
decreasing inflammation (76-82). Taken together these studies illustrate that P4, by decreasing 
inflammation and pro-inflammatory cytokines, limits non-infectious diseases caused by excessive 
	   10  
inflammation, such as some autoimmune diseases, and improves the outcome of brain injuries 
and stoke by promoting repair. 
The Effects of Progestins on Infectious Diseases at Mucosal Sites 
Background 
Mucosal sites are characterized by the presence of a mucous membrane composed of 
epithelial cells that provide both a physical barrier and early production of innate immune 
defenses, including mucous and antimicrobial secretions. The epithelia also contains local 
mucosal-associated lymphoid tissues (MALTs) that resemble lymph nodes and serve as the 
inductive sites for the adaptive immune response (83). Mucosal sites are present throughout the 
body and include the respiratory tract, the gastrointestinal tract, the female reproductive tract, the 
eyes and the nose. They are particular vulnerable to infections as they come in contact with the 
exterior of the body and as such, form the main route of entry for infectious agents invading the 
host (Table 1.3) (84). In additional to being exposed to pathogens, mucosal sites are continuously 
exposed to commensal bacteria which need to induce tolerance mechanisms rather than initiate an 
immune response to avoid excessive and constant inflammation (85). Induction of a mucosal 
immune response generally occurs at inductive sites where antigen is captured by antigen 
presenting cells that can carry the antigen via the lymphatics to the local draining lymph node 
where it can be presented to naïve T and B cells and initiate adaptive immune responses. These 
activated T and B cells then need to traffic back through the bloodstream to the local mucosal 
sites, directed by homing signals including a4b7 and CCR9 (86, 87). Production of IgA at the sites 
of infection involves the production of the polymeric IgA receptor by epithelial cells which 
allows for transport of IgA across the mucosal barrier and the generation of an IgA dimer (88, 
89).  Similarities between the different mucosal sites, termed “the common mucosal immune 
system” involve the homing of antigen-specific cells to a mucosal effector site different than 
where the antigen was first sensed (90). This is important in vaccination contexts where oral 
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vaccination can also protect against infections at other sites than the gastrointestinal tract (91). In 
this chapter, I will be describing the role of progestins at various mucosal sites which can be 
found summarized in Table 1.3. Despite these mucosal sites being anatomically distinct 
compartments, the similarities in mucosal immune responses may allow for us to draw parallels 
between the responses that occur at different sites.  
Urogenital tract 
Epidemiological studies show that when compared with males, females have higher rates 
of sexually transmitted infections (STIs), including human immunodeficiency virus (HIV), herpes 
simplex virus (HSV), gonorrhea, and chlamydia. The different stages of the menstrual cycle along 
with the use of hormonal contraceptives have been shown in both human and animal models to 
increase susceptibility to STIs (92, 93) and progestins have been implicated as a factor that may 
contribute to this heightened susceptibility (94-97). Many reasons have been proposed for these 
negative effects of progestins on STIs including thinning of the vaginal epithelium (98, 99), 
increases in virus entry co-receptors (100-102), and induction of an anti-inflammatory cytokine 
milieu lacking essential anti-microbial, pro-inflammatory cytokines such as IFN-g and TNF-a 
(97, 101).  
The effects of progestins have been extensively studied in the context of HIV, where 
multiple epidemiological studies, in vivo studies in non-human primates, and in vitro studies have 
assessed the effects of progestins on the outcome of HIV acquisition, transmission, and virus 
replication. In both humans and non-human primates, the risk of HIV acquisition is increased in 
females during the luteal phase of the menstrual cycle, when P4 is at its highest levels, and 
following use of hormonal contraceptives containing progestins (103-106). In non-human 
primates, there is an increased risk of simian immunodeficiency virus (SIV), and higher viral 
loads following P4 treatment  (97, 107).  In macaques treated with DMPA, acute viremia and 
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transmission of multiple viral variants is increased concomitantly with a decrease in virus-specific 
IFN-g production (97). In women taking DMPA, levels of the chemokine CCL5 are significantly 
increased in cervical swabs, but concentrations of pro-inflammatory cytokines such as IL-1b or 
IL-6 remain similar to women not taking contraceptives (48). In vitro data show that treatment of 
PBMC with P4 leads to increased expression of the HIV receptor CXCR4 but not CCR5 in both 
HIV infected and non-infected women (102). Genital epithelial cells also have a higher uptake of 
HIV by endocytosis when exposed to P4 and to a greater extent with MPA (108).  
Huijbregst et al. studied extensively the effects of either P4 or MPA in human peripheral 
blood mononuclear cells (PBMCs) and cervical lavages. They found that upon activation with 
cytokine-coated activating beads, PBMCs treated with MPA had reduced IFN-g, IL-6, IL-12, IL-
17 and TNF-a production, and both MPA and P4 reduced IL-2 and IL-4 production (101). When 
these PBMCs were treated with P4 and infected with HIV, MPA but not P4 increased viral titers 
(101). Additionally, cervicolavage fluid from women taking DMPA has decreased concentrations 
of IFN-a as compared with  concentrations in women not taking any form of contraceptive, 
which mirrors the suppressive effects of progestins on type I IFN production by plasmacytoid 
DCs following stimulation with TLR ligands (101).  
Many of the epidemiological studies of progestins and HIV focus on women using 
DMPA, which may increase the risk of HIV acquisition, but more recent meta-analysis studies 
found that overall progestin-based hormonal contraceptives do not increase the risk of HIV 
acquisition or disease progression (104, 109-112). It could be that DMPA promotes HIV 
acquisition via a modulation of the immune response through the glucocorticoid but not the 
progesterone receptor signaling. Progestins can have their biological effects through either the 
glucocorticoid or progesterone receptor and all progestins bind to these receptors with different 
affinities (14).   
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 Herpes simplex virus (HSV) is the most commonly transmitted STIs and progestins can 
increase susceptibility and decrease protection during HSV vaccination (92, 95, 96, 113-116). 
Studies in ovariectomized mice show that DMPA leads to HSV-1 reactivation, with a decrease in 
numbers of virus-specific neuronal CD8+ T cells and their ability to control the virus including 
their lytic capacity and production of the antiviral cytokines IFN-g and TNF-a (95). DMPA also 
impairs the CD8+ T cell response by decreasing the expression of co-stimulatory molecules on 
DCs (117). In mice, treatment with either DMPA, P4, or LNG increased susceptibility to HSV-2 
by increasing levels of IL-1b and inflammation and enhancing mucosal permeability to facilitate 
entry of inflammatory cells by reducing the expression of the cadherin desmoglein-1a (116, 118, 
119). Human primary genital epithelial cells are highly susceptible to HSV-2 infection but unlike 
murine models, P4 treatment is protective and limits virus shedding as compared to control-
treated cultures (120). In the context of HSV-2 vaccination, DMPA and P4 decrease anti-HSV-2 
IgG and IgA in vaginal washes, increase viral shedding, and fail to protect mice following HSV-2 
challenge as compared to estradiol-treated mice (113, 118, 119).  
In rats, P4 increases susceptibility to the bacterium Chlamydia trichomatis by increasing 
inflammation, production of IFN-g and IL-10, and pathogen load (94, 121). In women using 
DMPA, susceptibility to infection with Neisseria gonorrhea is significantly decreased (122), but 
treatment of primary human cervical cells with P4 increases the ability of the bacteria to survive 
by increasing AKT activity and iNOS production (123). When P4-treated female mice are 
infected with N. gonorrhea, bacterial loads and duration of infection are increased with increasing 
levels of thymic stromal lymphopoietin (TSLP) and Tregs and decreasing Th17 cell responses 
(124). Vaginosis can be caused by many pathogens, the most common being Candida albicans; 
P4 and progestin-based hormonal contraceptives have all been shown to be beneficial by reducing 
prevalence and incidence of vaginitis (125). In vitro studies show that P4 can decrease C. 
albicans biofilm formation thus preventing colonization and invasion of the vaginal mucosa 
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(126). Taken together these data show that the anti-inflammatory properties of progestins may 
lead to increased susceptibility to STIs, but the type of progestin may affect the risk of acquisition 
or disease progression differentially.  
Gastrointestinal Tract 
A limited number of studies have accessed the role of progestins in the gastrointestinal 
tract, with focus being on either bacteria or parasitic infections. In the context of murine infection 
with Salmonella typhimurium, the causative agent of typhoid, P4 treatment increases host survival 
by increasing cellular infiltration and promoting clearance of the bacteria (127). Similarly, 
following infection of hamsters with the parasite, Taenia solium, P4 increases host survival and 
decreases tapeworm length by recruiting mast cells and increasing levels of the pro-inflammatory 
IL-4, IL-6, and TNF-a in the intestinal mucosa which can promote parasite elimination (128). In 
the context of gastritis due to Helicobacter pylori infections, P4 reduces gastrointestinal 
inflammation in ovariectomized gerbils and reduces the effects of gastritis (129). In summary, 
progestins may be protective against gastrointestinal infections by increasing host survival 
through their immunomodulatory effects.  
Respiratory Tract 
To date, only two studies have assessed the role of progesterone or progestins on 
infectious diseases in the respiratory tract. The first study looked at the effect of DMPA on the 
outcome of a Mycobacterium tuberculosis infection and found that DMPA can increase the viral 
load by inducing an anti-inflammatory environment with a decrease in the production of TNF-a, 
IFN-g, and G-CSF (130). The second study is from this thesis, in which administration of P4 to 
ovariectomized mice prevented severe outcome from influenza A virus infection by decreasing 
inflammation and promoting repair of the pulmonary tissues through the epithelial growth factor 
amphiregulin (AREG), which is the focus of the work described in chapter 1 (131). Antibody 
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titers and memory CD8+ T cell responses are also decreased following treatment of ovary-intact 
mice with either P4 or LNG, which results in greater susceptibility to a challenge with a 
heterologous virus and will be the focus of chapter 2 (132).  
These results show that progestin can reduce inflammation in the respiratory tract, which 
is detrimental in the context of tuberculosis, but beneficial during influenza A virus infection. 
This discrepancy may depend on whether control of severe disease requires a strong pro-
inflammatory response to clear the pathogen (e.g., tuberculosis) or causes excessive inflammation 




Table 1.3: The effects of progestins on viral, bacterial, and parasitic infections of mucosal sites 








­ Risk acquisition and transmission 
­ Virus uptake by genital epithelial   
cells 
¯ Risk of acquisition in some 
human studies 
¯ Innate and adaptive immunity 
¯ IFN-g, TNF-a, IL-2, IL-4, IL-6 
IL-12, MIP-1a, TNF-a, ¯ IFN-a 
¯ IFN-a and TNF-a production in 
pDCs 




P4 ¯ HIV replication in human trophoblasts 
­ Presence of CXCR4 
­ or ¯ CCR5 
¯ TNF-a, IL-2 and IL-4 
(100, 102, 
133)  







P4 ­ Transmission 
­ Viral Loads ¯ Epithelium lining 
(107) 
DMPA ­ Susceptibility 
­ Acquisition and shedding ¯ IFN-g secreting CD8 T cells 
(97) 
Herpes Simplex 





DMPA ­ Virus reactivation   
¯ Virus-specific CD8 T cells 
¯ IFN-g and TNF-a 
¯ Granzyme B and lytic granules 
¯ Macrophages, NK and NKT cells 











­ Virus shedding  
­ Pathogenesis  
¯ Protection of HSV-2 vaccine  
¯ IgG and IgA levels 
­ IL-1b, CXCL7, CXCR1 
­ IL-10 




¯ Protection of vaccine against 
challenge 
¯ Virus shedding 
­ Neutrophil infiltration 
­ CCL5, CXCL2, CCL2, CXCL10 
(113, 114, 
120) 








P4 ­ Susceptibility  
­ Pathogen load 
­ Inflammation 










­ Bacterial load in primary human 
cervical epithelial cells 
­ Length of infection in mice 
­ TSLP 
­ Regulatory T cells 
¯ Th17 cells 
­ Production of nitric oxide 
(123, 124) 






















­ Survival of the host 
­ Resistance  
­ Clearance of bacteria 













­Host survival by increasing 
inflammation 
¯ Parasite load 
­ Proliferation of parasite-specific 
leukocytes 















¯ Pathogenesis and severe outcome 
­ Host survival 
­ Repair and pulmonary function 
­ TGF-b, IL-6, IL-22 
­ Amphiregulin 
­ Th17 cells 
(131) 
 
Key: P4 = progesterone, DMPA = depot medroxyprogesterone acetate, LNG = levonorgestrel, Net-EN = norethisterone oenanthate, N/A= not 
available 
	   18  
Influenza A virus 
Background 
Influenza A viruses (IAV), along with influenza B, C and D are part of the 
Orthomyxoviridae family, with subtype A being the main cause of zoonotic and human infections 
(134, 135). Influenza viruses are enveloped segmented single stranded RNA (ssRNA) viruses and 
the surface of the virion is composed of the hemagglutinin (HA) and neuraminidase (NA), which 
define the different influenza A virus subtypes (134). A combination of 18 different HA and 9 
different NA subtypes have been found in circulating influenza A viruses (136). IAVs can also be 
further characterized based on their antigenic properties and as such, HA proteins are further 
divided into two phylogenetic groups: group 1 which includes H1, H5 and H9 and group 2 that 
contains H3 and H7 for example (136). Along with the HA and NA, the matrix 2 (M2) protein is 
also part of the envelope. The matrix protein 1 (M1) lies just beneath the envelope, and the core 
of the virus is composed of the ribonucleoprotein complex (which contains the viral RNA) which 
is encapsidated by the nucleoprotein (NP), the polymerases (PA, PB1 and PB2), and the nuclear 
export protein NS2 (134).  
Influenza A viruses are found mainly in waterfowl which are the primary reservoir, but 
these viruses also circulate in birds, swine, humans and other mammals (e.g., bats, cattle and 
seals), and can be transmitted across species (137, 138). Host specificity as well as tissue tropism 
is determined by the binding of the HA to sialic acid (SA) on the surface of epithelial cells. For 
example, human IAVs HA bind preferentially to a2,6-Gal terminated SA, avian IAVs HA binds 
to a2,3-Gal terminated SA, and swine IAVs HA bind to both SAs (135, 139). The sporadic 
emergence of a new human-adapted IAV from a zoonotic virus is usually the cause of worldwide 
pandemics such as the 1918 Spanish flu (H1N1), 1957 Asian flu (H2N2), the 1968 Hong Kong 
flu (H3N2) and the 2009 H1N1 pandemic (135). Aside from the severe impact of these sporadic 
pandemics, seasonal influenza infections cause over 200,000 hospitalizations and up to 36,000 
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deaths each year in the United States alone (140). The economic impact of IAV infection is also 
very important with an estimated 8 billion dollars in loss not only due to hospitalizations but also 
projected lost earnings in the United States (141). Currently, there are two IAV subtypes 
circulating in humans: the H1N1 and H3N2 viruses as well as either one or two influenza B 
viruses and all are contained in the annual seasonal influenza vaccine (142). New IAV variants 
also emerge from point mutations in the HA or NA that occur during virus replication through a 
process termed antigenic drift, as these enable the virus to evade the host immune response 
despite pre-existing antibodies to the original strain (143, 144). For example, circulating viruses 
from the 2009 H1N1 pandemic acquired a K166Q mutation in the HA during the 2012-2013 
influenza season and this antigenic variant is now present in 99% of all pandemic H1N1 isolates 
(145).  
Innate immune responses to influenza A viruses 
The first line of defense against any respiratory pathogens is formed by the barrier 
provided by the epithelial cells that line the respiratory tract which includes the nose, trachea and 
lungs, along with the mucus and other antimicrobial compounds they produce (146). Aside from 
being the first barrier that the viruses encounter, epithelial cells are also the primary cell type that 
IAV can infect, and replicate in (147). This leads to lysis of these virus-infected epithelial cells 
either directly by the virus itself or from targeting by immune cells, which induces the destruction 
of the pulmonary epithelium (143). Influenza A viruses can cross the epithelial barrier and be 
sensed by antigen-presenting cells, such as macrophages and DCs, which can initiate an adaptive 
immune response by presenting viral antigens to T cells (148, 149).  
 Tissue-resident alveolar macrophages are another line of defense against IAVs and 
promote viral clearance through phagocytosis of either opsonized viral particles or virus-infected 
apoptotic cells. During steady-state conditions, alveolar macrophages help maintain lung 
homeostasis; following IAV infection, these cells polarize towards an M1 inflammatory 
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phenotype and produce TNF-a and iNOS and contribute to viral clearance (150, 151). Depletion 
of M1 macrophages by deleting CCR2+ cells reduces the severity of IAV infection with 
decreased production of IL-6, TNF-a and CCL2 (152). Paradoxically, depletion of alveolar 
macrophages by clodronate liposomes prior to IAV infection leads to increased mortality by 
respiratory failure and uncontrolled viral replication with reduced numbers of virus-specific 
CD8+ T cells (153-157). This demonstrates that alveolar macrophages are essential during IAV 
infection but in excess can also lead to alveolar injury. Similarly, depletion of neutrophils leads to 
increased morbidity and mortality despite the fact that exacerbated IAV pathology is linked to 
increased neutrophil infiltration (153, 158, 159). Neutrophils are necessary for virus clearance 
and control of inflammation as studies depleting neutrophils in mice have shown increased 
mortality, virus titers, and pulmonary immunopathology (160, 161). However, like macrophages, 
excessive infiltration of neutrophils can be deleterious, therefore neutrophils are necessary but in 
excess can also cause immunopathology (153, 160, 161).   
Lung resident DCs play an important role during IAV infection and can acquire antigen 
either directly by infection with IAV, or by phagocytosis of virus-infected epithelial cells, and 
have been shown to be better antigen-presenting cells than macrophages (148, 162). CD103+ 
DCs reside in the pulmonary epithelium, sample virus particles in the airway lumen, and can 
migrate to the lymph nodes to present viral antigen and activate naïve CD4+ and CD8+ T cells by 
cross-presentation (163, 164). TNF-a and nitric oxide producing DCs (TiP DCs) are increased in 
the lungs following infection highly pathogenic IAV strains and also play a role in the priming of 
virus-specific CD8+ T cells (165). Dendritic cells can also control IAV infections and contribute 
to excessive pathology by the production of pro-inflammatory cytokines including IL-6, TNF-a, 
and type I IFNs (148). The sensing of IAV in epithelial and antigen-presenting cells occurs 
through PRRs, including TLRs and RIG-I-like receptors (RLRs). For example, TLR7 senses 
ssRNA in the endosomes when the ribonucleoprotein is release from the IAV particle (166). At 
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later stages of infection, the retinoic acid inducible gene-1 (RIG-I) receptors recognizes the 
uncapped 5’triphosphate RNA of the virus in the cytosol (166). These PRR pathways lead to the 
activation of either the NK-kB or IRF3/7 pathways to induce the production of pro-inflammatory 
cytokines including TNF-a, IL-6, type I and type III IFNs and chemokines, such as CCL2 and 
CCL3 (148, 167, 168). IAV infection also triggers the inflammasome pathway through either an 
M2-induced proton flux, or sensing of ssRNA, and leads to the production of IL-1b and IL-18 
(169, 170). Additional antiviral sensors, triggered and amplified by type I IFN signaling, are key 
in the immune response to IAV, including the RNA-dependent protein kinase R (PKR) which 
limits viral replication by blocking cellular translation, and 2’,5’-oligoadenylate synthase (2’,5’-
OAS) that activates RNAse L and degrades viral and cellular RNA leading to apoptosis of the 
virus-infected cell (171, 172). IAVs have evolved a multitude of evasion mechanisms that act at 
many different levels of these PRR pathways, including the NS1A protein that inhibits RIG-I by 
preventing oligomerization of the CARD domain of RIG-I (171, 173). The production of these 
pro-inflammatory cytokines and chemokines in the lungs during IAV infection can lead to the 
recruitment of cells from the periphery and activation of local resident cells to produce a pro-
inflammatory environment and promote viral clearance (148). However, in excess these pro-
inflammatory responses can lead to extensive pulmonary tissue damage and these responses need 
to be balanced to avoid immunopathology while allowing virus clearance. Innate immune 
responses to IAV are not sufficient to resolve IAV infection and require the help of the adaptive 
immune responses with a combination of cytotoxic CD8+ T cells, CD4+ T cells and production 
of antibodies by B cells at the site of infection (149).  
Adaptive immune response to influenza A viruses 
Protective adaptive immune responses to IAV infections, include antibodies and T cell 
responses. Protection during primary IAV infection is mediated by cellular immune responses 
including macrophages and T cells and prevention of re-infection is correlated with anti-influenza 
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specific antibodies and as such are a relative correlate of protection. Antibodies recognize the 
envelope proteins HA and NA, which are the immunodominant proteins of the virus, generate 
long-lasting protective immunity by preventing virus attachment and entry (for antibodies against 
HA) and limit viral spread (for antibodies against NA) (174-176). Most antibodies against the HA 
bind the highly variable globular head domain of the protein which is in proximity of the 
receptor-binding domain, and only confer strain-specific protection (177). More recently, broadly 
neutralizing HA antibodies targeting the conserved stalk domain have been discovered in mice, 
humans and ferrets, and mediate cross-protection against IAV within the same HA phylogenetic 
groups (178-182). Antibodies against the internal NP protein are generated later during infection 
are non-neutralizing and promote protection through antibody-dependent cellular cytotoxicity 
(ADCC) (183). Human studies show the presence of both virus-specific IgA and IgG antibodies 
in nasal washes following IAV infection; IgG alone, however, is not sufficient to reduce viral 
shedding in the nasal cavity. Secretory IgA-mediated protection more than IgG provides 
protection against IAVs in the lungs (184-186). 
 Naïve CD4+ T cells differentiate into different Th subsets following IAV infection and 
support the formation of both virus-specific CD8+ T cells and antibody-secreting B cells. Th1 
cells, which produce IFN-g and IL-2, are involved in promoting cytotoxic CD8+ T cells which 
control IAV replication, and help with the promotion of B cell isotype switching from IgG1 to 
IgG2a or IgG2b, which induce a better protection during IAV infection (187-190). Th17 cells 
play a protective role in the immune response to IAV through the production of IL-17 which 
leads to an increase in antimicrobial peptides, proliferation of lung epithelial cells, and 
recruitment of neutrophils (191-193). Memory CD4+ T cells play a role in heterosubtypic 
responses to IAV by enhancing protection through the secretion of IFN-g and faster virus 
clearance independent of CD8+ T cell responses (194). Additionally, virus-specific memory 
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CD4+ regulatory T cells actively recruited to the lungs following a secondary IAV infection and 
control the proliferation of memory CD8+ T cells to dampen inflammation (195). 
Cytotoxic CD8+ T cells control IAV infection by producing antiviral cytokines, 
including IFN-g and TNF-a, and lysing virus-infected cells (196, 197). CD8+ T cells can target 
virus-infected cells for lysis in three different ways:1) in a granzyme- and perforin- dependent 
manner, 2) using the Fas/FasL pathway, and 3) via the TNF-related apoptosis-inducing ligand 
(TRAIL) pathway (197, 198). Virus-specific CD8+ T cells alone are capable of clearing IAV 
infections, independent of neutralizing antibodies (197, 199). CD8+ T cells recognize epitopes 
derived from internal proteins, and studies using ex vivo stimulation of human PBMCs have 
shown that peptides from the M1 and NP proteins are the major targets for T cell immunity 
against IAV (200-202). Memory CD8+ T cells have the ability to target a broad range of peptides 
derived from IAV proteins that can be relatively well conserved, such as the nucleoprotein to 
provide immunity against a broad range of distinct IAV strains and induce heterologous 
immunity against novel IAV strains (180, 203-205). In addition to circulating memory T cells, 
and central memory T cells which traffic through the lymph nodes, the role of tissue-resident 
memory cells in promoting a local and immediate protection in the lungs during IAV infection 
with the ability to expand rapidly, kill virus-infected cells, recruit circulating memory T cells, 
release cytokines has been shown to be indispensable in generating both homotypic and 
heterosubtypic protection (206-208). Other adaptive immune cell types, including inducible 
natural killer T (iNKT) cells have a protective role during IAV pathogenesis, through the 
production of IL-22 which leads to repair and protection of the epithelial barrier (209). 
Risk factors for severe influenza  
A number of host factors contribute to IAV severity including sex, age, obesity, 
pregnancy, asthma, and the presence of co-morbidities (210-215). Females generally mount 
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higher immune responses than males with greater antibody and cellular immune responses and 
reduced susceptibility and viral loads following viral infection (211, 216, 217). However, during 
infection with viruses such as IAV, in which severe disease is caused by immunopathology, this 
heightened immunity may be unfavorable. In both human and murine models of IAV, females are 
more likely to develop severe disease than males (214, 218, 219). During the 2009 H1N1 
pandemic for example, in adults (20-70 years of age), females had higher hospitalization rates, 
longer length of stay and increased mortality as compare to males (220, 221). Adult female mice 
inoculated either with H1N1, H3N2, or H7N9 viruses have higher morbidity and mortality than 
males (218, 219, 222). Females have higher levels of pulmonary pro-inflammatory cytokines and 
chemokines including TNF-a, IFN-g, IL-6, and CCL2 than males during the acute phase of H1N1 
infection (222). Females infected with an H3N2 virus have higher levels of IFN-g and MCP-1 
during the acute phase of infection and impaired lung function than males (223). Similarly, 
females infected with an H7N9 virus mounted higher cytokine responses than males, including 
increased levels of IL-6, IL-9, TNF-a, MCP-1 and CCL-5 during the acute phase of infection 
(219). All three of these studies show no differences in viral titers between the sexes which 
suggests that it is the host immune response and not the virus which mediates the observed sex 
differences in morbidity and mortality (219, 222, 223). However, females sex steroid hormones 
alone do not explain these differences as both estrogens (E2 specifically) and P4 decrease pro-
inflammatory responses, including TNF-a and CCL2 during IAV infection (131, 158, 222).  
Pregnant women are 3 to 10 times more likely to be hospitalized, and are at greater risk 
of intensive care unit (ICU) admission and secondary bacterial infections as compared to age-
matched non-pregnant females (224-226). During the 2009 H1N1 pandemic for example, 
pregnant women were at greater risk of a severe outcome, with approximately 80% of maternal 
deaths occurring during the third trimester of pregnancy (227-230)  Although the outcome of 
seasonal influenza virus infection is less severe than the outcome of pandemic influenza viruses, 
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pregnant women have a longer length of hospitalization from infection with seasonal influenza 
viruses (231). This increased susceptibility to IAV may be due to changes in the immune status 
during pregnancy where the local and systemic environment shift towards an anti-inflammatory 
milieu in order to sustain a healthy pregnancy and avoid fetus rejection. This shift towards an 
anti-inflammatory environment is characterized by an increase in CD4+ Th2 and Tregs (232-
236). Studies looking at IAV during pregnancy show a decrease in plasmacytoid DCs leading to a 
downregulation of cytotoxic CD8+ T cells and IFN-g production in humans and mice (237). In a 
pregnant mouse model, IAV increased numbers of pulmonary macrophages and Tregs as 
compared to non-pregnant mice (213). Pregnant mice infected with ma2009 H1N1 have greater 
mortality and production of pro-inflammatory cytokine and chemokines in the lungs, including 
TNF-a, CCL2, CCL3, CXCL1, as compared with non-pregnant female mice (213, 238, 239). 
Whether control of virus replication is diminished during pregnancy is not clear because data 
regarding differences in viral loads are contradictory (213, 238). These immune changes parallel 
increases in sex steroid hormones, including estrogens and progesterone as well as anatomical 
and physiological changes which increase cardiopulmonary demands and all of these changes 
may contribute to an increased risk of severe IAV outcome during pregnancy (225, 240-242).  
Similarly to pregnant individuals, obesity is also associated with respiratory 
complications and higher hospitalization rates during infection with seasonal and pandemic IAVs 
(215). Studies in mice have shown that both diet-induced and genetically obese mice have 
increase morbidity with severe lung pathology associated with impaired pulmonary wound repair, 
higher viral titers and dysregulated memory CD8+ T cells responses (212, 243, 244). Studies in 
both mice and humans also show that obesity impacts antibody responses and lowers 
responsiveness to influenza vaccination (244-246). This impaired response to IAV in obese 
subjects is thought to be a combination of immune dysregulation and decreased lung function 
(215, 243).  
	   26  
Animal models for influenza A virus 
In order to better understand IAV pathogenesis, risk factors, vaccine responses and 
antiviral efficacy, a variety of animal models are commonly used, with mice and ferrets being the 
preferred models (247, 248). Mice are the most widely used models as they are practical, small, 
relatively inexpensive, and develop similar immune responses, despite the lack of IAV 
transmission and different clinical presentation than humans (247, 248). Clinical signs of IAV 
infection in mice include: weight loss, hypothermia, ruffled fur, lethargia, huddling, and dyspnea 
(131, 158, 222). Viruses generally need to be mouse-adapted, except for highly pathogenic 
strains, as mice and humans both have a2,3-linked SA in ciliated and type II alveolar epithelial 
cells but the a2,6-linked SA, which is the preferred receptor for human viruses is not present in 
mice (249). Influenza virus are mouse-adapted through serial passage in mice to increase receptor 
binding and virulence by generating amino acid mutations (250, 251). Inbred mice lack the Mx1 
gene, which makes them more susceptible to IAVs, unlike wild mice (252, 253).  
Ferrets have been used in influenza research since the 1930s and represent a more 
accurate animal model of IAV transmission, have similar clinical symptoms to humans, and do 
not require prior virus adaptation due to similarities in their sialic acid distribution (254-259). 
They are widely used to determine antigenicity of IAV vaccines and for testing of new antiviral 
drugs (254, 257, 260). Guinea pigs are another animal model that support IAV transmission but 
lack clinical signs of disease (247). Syrian hamsters were used in the 1960s and 1980s to analyze 
antibody responses to IAV but do not transmit IAVs (247). Pigs are a natural reservoir for IAV 
but lack practical aspects for animal husbandry and are mainly used in the development of swine 
IAV vaccine and have the advantage of supporting the infection of most IAV subtypes (261). 
Non-human primates are rarely used but are also susceptible to human IAVs and are used in 
vaccination studies (247, 248, 262). Despite differences in clinical symptoms, transmission and 
immune responses between animal models and humans, they serve as a good surrogate and allow 
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to investigate different aspects of IAV infection, pathogenesis, transmission and vaccination. The 
greatest caveat with all these models is that they are influenza naïve and studies have shown that 
humans by age six have all been exposed to IAVs which is something that needs to be considered 
in animal models of IAV (263). 
Influenza A virus pathogenesis 
Influenza A viruses cause an acute respiratory infection typically characterized by virus 
replication in respiratory epithelial cells, initiation of a ‘cytokine storm’ with production of IL-1b, 
TNF-a, IFN-a, IL-6 and CCL2 in the host, and long-term damage to pulmonary tissues (264, 
265). This pulmonary inflammation is characterized by edema, bronchitis, lung fibrosis, diffuse 
alveolar damage, infiltration of immune cells and death of epithelial cells which threatens proper 
gas exchange and pulmonary function (153, 265-268).The typical presentation of influenza in 
adults and children is an abrupt onset of fever and chills along with headaches, sore throat and 
myalgia (143). In the most severe cases of IAV, excessive pulmonary infiltrates and hypoxemia 
can lead to acute respiratory distress syndrome (ARDS) which accounts for 4% of all 
hospitalization for respiratory failure during influenza infections (269, 270). Long after the 
symptoms of disease have subsided, pulmonary tissue damage can persist and increase the risk of 
secondary bacterial infections (265, 271). The 2009 H1N1 pandemic, in particular, was associated 
with increased inflammation and pulmonary tissue damage requiring extensive tissue repair 
(272). Protection requires a balance between inflammatory responses generated to clear the virus 
and those that repair the damage cause by cellular infiltration and the local protein mediators. 
Repair of damaged tissue involves a complex interplay among many cells, cytokines, 
chemokines, growth factors, and extracellular matrix proteins that serve to remodel tissue (273, 
274). Repair of the damage induced in the lungs following IAV infection is generally orchestrated 
by macrophages, Tregs, and associated cytokines, including IL-10, IL-22 and TGF-β, along with 
remodeling by epithelial cells (275). Recent studies in both gastrointestinal and respiratory 
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mucosa have demonstrated a crucial role for IL-22 as a gatekeeper to promote epithelial integrity 
by promoting cellular proliferation and production of antimicrobial peptides (276-278). During 
IAV infection, IL-22 is essential for promoting repair of damaged epithelial and recovery to a 
healthy lung function. This was demonstrated in IL-22 KO mice infected with H1N1, where the 
lack of IL-22 led to increased morbidity, worsened lung injury, and increased edema without 
affecting pulmonary virus titers as compared to wild-type mice (277). In addition to cytokines, 
damaged epithelial cells release factors, including the epidermal growth factor-like molecule, 
amphiregulin (AREG) that promote repair and remodeling of lung tissue damaged during IAV 
infection (279, 280). AREG is involved in pulmonary tissue remodeling and repair during many 
different aspects of lung pathology including lung injury, asthma, and infection (273, 279-286). 
During IAV infection, administration of recombinant AREG protects mice from severe IAV 
infection by decreasing hypothermia, improving pulmonary function, and decreasing protein 
leakage into the airways (131, 279, 280).  AREG is produced primarily by epithelial cells (131, 
287), but type 2 innate lymphoid cells (ILC2) and Tregs have also been shown to produce AREG 
during IAV infection and contribute to the repair during resolution of infection (279, 280, 287, 
288). 
Taken together, these data suggest that the clearance and resolution of IAV infection 
relies on a delicate balance of pro- and anti- inflammatory mediators with any dysregulation 
towards exacerbated inflammation leading towards severe influenza illness and sequelae to the 
lungs. I hypothesize that given its anti-inflammatory role and repair role, P4 may help tilt the 
balance towards a dampening of inflammation, thus protecting the respiratory epithelium while 
inducing repair, without compromising the immune response necessary to clear the virus.  
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Specific Aim 1 
Progesterone has immunomodulatory and reparative properties in the reproductive tract 
and in the central nervous system, that have yet to be evaluated in in the respiratory tract. I 
hypothesized that administration of progesterone to progesterone-depleted female mice would 
impact the outcome of influenza A virus infection by dampening inflammation and promoting 
pulmonary repair. Specifically, the dampening of the exacerbated inflammation by progesterone 
during lethal influenza A virus infection would protect these mice from succumbing to the 
infection, and promote production of cytokines, such as TGF-b and IL-22, that lead to the repair 
of epithelial cells without impacting virus replication.  
To further assess the role of progesterone in repair, I used a non-lethal influenza A virus 
model to evaluate the effects of progesterone during the recovery phase and I hypothesize that 
administration of progesterone would both dampen the inflammation during the peak of infection, 
and promote repair during the recovery phase to hasten the repair of pulmonary tissue damage 
and lead to a faster recovery of lung function. Progesterone can promote the production of the 
epidermal growth factor amphiregulin which has also been shown to promote repair and recovery 
from influenza A virus infection. I hypothesized that the reparative effects of progesterone 
following influenza A virus infection would be mediated by upregulated amphiregulin, a critical 
protein for the proliferation of epithelial cells, to repair the damaged epithelium and promote 
recovery.  
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Specific Aim 2 
My findings from Specific Aim 1 indicated that progesterone has a positive effect on 
primary influenza A virus infection by dampening inflammation and promoting repair. I wanted 
to further evaluate the effect of this anti-inflammatory environment on the induction of a memory 
humoral and cellular immune response. I hypothesized that by dampening inflammation, 
progesterone may hinder the generation of an optimal memory immune response. Few studies 
have evaluated the effects of progesterone on antibody production and those that have, show that 
progesterone decreases antibody responses. To date, no studies have assessed the effects of 
progesterone on memory CD8+ T cells responses. I hypothesized that progesterone would 
decrease total and neutralizing virus-specific antibodies and may impact protection following 
challenge with a secondary influenza A virus by lowering memory CD8+ T cells. 
 In this Specific Aim 2, after pilot studies showed that progesterone and related 
compounds worked equally well in ovariectomized and ovary-intact female mice, I elected to use 
ovary-intact mice to assess the effects of progesterone on influenza A virus infection and memory 
responses. For these studies, I also evaluated the effects of a synthetic progestin, levonorgestrel, 
on the outcome of influenza A virus infection. This progestin is widely used in hormonal-based 
therapies and binds to the progesterone receptor with a greater affinity than progesterone. I 
hypothesize that levonorgestrel, like progesterone, would dampen inflammation and promote 
protection from a primary influenza A virus infection with the caveat of decreasing antibody 
production and memory CD8+ T cell responses and protection against secondary infections.  
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Abstract 
Over 100 million women use progesterone therapies worldwide. Despite having 
immunomodulatory and repair properties, their effects on the outcome of viral diseases outside of 
the reproductive tract have not been evaluated. Administration of exogenous progesterone (at 
concentrations that mimic the luteal phase) to progesterone-depleted adult female mice conferred 
protection from both lethal and sublethal influenza A virus (IAV) infection. Progesterone 
treatment altered the inflammatory environment of the lungs, but had no effects on viral load. 
Progesterone treatment promoted faster recovery by increasing TGF-β, IL-6, IL-22, numbers of 
regulatory Th17 cells expressing CD39, and cellular proliferation, reducing protein leakage into 
the airway, improving pulmonary function, and upregulating the epidermal growth factor 
amphiregulin (AREG) in the lungs. Administration of rAREG to progesterone-depleted females 
promoted pulmonary repair and improved the outcome of IAV infection. Progesterone-treatment 
of AREG-deficient females could not restore protection, indicating that progesterone-mediated 
induction of AREG caused repair in the lungs and accelerated recovery from IAV infection. 
Repair and production of AREG by damaged respiratory epithelial cell cultures in vitro was 
increased by progesterone. Our results illustrate that progesterone is a critical host factor 
mediating production of AREG by epithelial cells and pulmonary tissue repair following 
infection, which has important implications for women’s health.  
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Author Summary 
Worldwide, the use of hormonal contraceptives is on the rise as a primary intervention 
for improving women’s health outcomes through reduced maternal mortality and increased 
childhood survival. There are many hormone contraceptive formulations, all of which contain 
some form of progesterone. Although the effects of hormone contraceptives and progesterone, 
specifically, have been evaluated in the context of infections of the reproductive tract, the effects 
of progesterone at other mucosal sites, including the respiratory tract have not been systematically 
evaluated. We have made the novel observation that administration of progesterone to female 
mice depleted of progesterone confers protection against both lethal and sublethal influenza A 
virus infection. In particular, progesterone reduces pulmonary inflammation, improves lung 
function, repairs the damaged lung epithelium, and promotes faster recovery following influenza 
A virus infection. Progesterone causes protection against severe outcome from influenza by 
inducing production of the epidermal growth factor, amphiregulin, by respiratory epithelial cells. 
This study provides insight into a novel mechanistic role of progesterone in the lungs and 
illustrates that sex hormone exposure, including through the use of hormonal contraceptives, has 
significant health effects beyond the reproductive tract.  
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Introduction 
Hormonal contraceptives are listed as an essential medication by the World Health 
Organization (WHO)(289) because of the profound benefits these compounds can have on 
women’s health outcomes, including decreased rates of maternal mortality and improved 
perinatal outcomes and child survival, by widening the intervals between pregnancies (290). 
Hormonal contraceptive formulations vary, but all contain some form of progesterone (P4) either 
alone or in combination with estrogen. There are currently over 100 million young adult women 
on P4-based contraceptives worldwide (4), with the WHO projecting that over 800 million 
women will be using contraceptives, including P4-based contraceptives, by 2030 (290). Despite 
the staggering numbers of women taking these compounds, very few studies evaluate the impact 
of contraceptives on responses to infection or vaccination, especially in non-sexually transmitted 
diseases.  
Natural P4, produced by the ovaries during reproductive cycles, or synthetic P4 analogues 
found in contraceptives, signal primarily through progesterone receptors present on many cells in 
the body, including immune cells (e.g., NK cells, macrophages, dendritic cells (DCs), and T cells) 
as well as non-immune cells, such as epithelial cells, endothelial cells, and neuronal cells (12, 13). 
Human, animal, and in vitro studies show that P4 can alter the immune environment and promote 
homeostasis by decreasing inflammation and inducing anti-inflammatory responses. For example, 
in the presence of P4, macrophages and DCs have a lower state of activation, produce higher 
levels of anti-inflammatory cytokines, such as IL-10, and produce lower amounts of 
proinflammatory cytokines, such as IL-1b and TNF-a, as compared with placebo treated cells 
(33, 39). When either mice or cord blood cells from humans are treated with P4, the percentages 
of Foxp3+ regulatory T cells (Tregs) increase (57, 58). Although the immunomodulatory effects 
of P4-based therapies in the form of contraception have been studied in the context of sexually 
transmitted infections, including HIV and herpes simplex virus (92, 116, 291), the impact of P4 
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on the outcome of viral infectious diseases outside of the reproductive tract has not been 
considered in either humans or animal models. 
Influenza A viruses (IAVs) primarily infect respiratory epithelial cells and induce the 
production of proinflammatory cytokines and chemokines that recruit immune cells, causing a 
local proinflammatory environment (149). Infiltration and activation of CD4+ and CD8+ T cells, 
while necessary for the clearance of IAVs (149, 292, 293), can trigger inflammation and lead to 
tissue damage and severe outcomes from IAV infection (267). Protection requires a balance 
between inflammatory responses generated to control virus replication and eliminate virus-
infected cells with responses that mediate the repair of damaged areas of the lung. Repair 
involves a complex interplay among many cell types, cytokines, chemokines, growth factors, and 
extracellular matrix proteins that remodel tissue after acute injury, such as IAV infection (274). 
Amphiregulin (AREG) is an epidermal growth factor that has emerged as a significant mediator 
of tissue repair at mucosal sites, including the lungs (279, 280), gastrointestinal tract (282, 294), 
and reproductive tract (295, 296). Many immune cells produce AREG, but epithelial cells remain 
the principle producer of AREG following inflammation or tissue injury (273). If P4 can 
downregulate inflammatory immune responses and promote regulatory or tissue repair responses, 
then this hormone, at concentrations that reflect the luteal phase of the reproductive cycle, may 
improve the outcome of IAV infection. 
Epidemiological and experimental evidence suggest that young adult females suffer a 
worse outcome than males following IAV infection, which in mice is associated with infection-
induced suppression of reproductive hormones and excessive inflammatory immune responses in 
females (210, 222, 223). In addition to influenza, young adult females suffer a worse outcome 
than males from several autoimmune diseases, including multiple sclerosis (297). Paradoxically, a 
growing body of literature reveals that exogenous treatment of females (both humans and mice) 
with either estrogens or P4 limits inflammation and protects against infectious and autoimmune 
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diseases by decreasing inflammation and promoting repair (64, 222, 298, 299). In this series of 
studies, we show that treatment with sustained physiological doses of P4 protects females against 
IAV by reducing inflammation and improving pulmonary function, primarily through 
upregulation of AREG in epithelial cells. The observation that P4 regulates the cellular and 
molecular mediators of tissue repair at a mucosal site outside of the reproductive tract to restore 
tissue homeostasis after infection or injury has broad implications for women’s health. 
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Results 
Progesterone limits lung pathology and protects female mice against lethal IAV infection 
To analyze the effects of P4 on morbidity and mortality in female mice, we depleted P4 
by removing the ovaries and replaced P4 with subcutaneous pellets that delivered a continuous 
dose of physiological levels of P4 over the course of 21 days. Mice were subsequently mock-
infected or infected with a dose of IAV (PR8) that is uniformly lethal for P4-depleted mice. 
Circulating levels of P4 and uterine horn mass, a biomarker of circulating P4 levels (300), were 
assessed over the course of infection to confirm the continuous effects of hormone replacement. 
Exogenous replacement of P4 significantly increased and sustained plasma P4 concentrations 
within the normal physiological range (301) throughout the duration of the study. Both mock- and 
IAV-infected females treated with exogenous P4 had higher circulating concentrations of P4, 
greater uterine horn mass, and higher expression of progesterone receptors (Prs) in the lungs than 
either mock or IAV-infected females treated with placebo throughout the 21 days (Fig. 2.1 A and 
B; P<0.05).  
During the course of IAV infection, treatment of female mice with P4 mitigated the 
effects of infection on morbidity and mortality (Fig. 2.1C and D; P<0.05), with the average day 
of death being later for females treated with P4 (11.14±1.0 days post-infection [dpi]) as compared 
to placebo-treated females (9.5±0.6 dpi) (P<0.05). Progesterone treatment did not alter virus titers 
over the course of the first week of infection as compared to placebo treatment (Fig. 2.1E), 
suggesting that P4 did not render females more resistant to IAV infection. To test whether P4 
improved survival during IAV infection by making females more tolerant to the negative 
consequences of infection on host health, we analyzed the interaction between virus titers and 
body temperature during peak disease (7dpi) (302). Females treated with P4 suffered less 
hypothermia relative to their pulmonary viral load than the placebo-treated females, suggesting 
that P4 made females more tolerant of IAV infection (Fig. 2.1F; P<0.05). To test the hypothesis 
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that P4 may increase tolerance by reducing inflammation and damage in the lung, pulmonary 
tissue was evaluated for vasculitis, bronchiolitis, alveolitis, and edema. In mock-infected animals, 
P4 alone did not result in changes in any of the parameters examined (Fig. 2.1G [panels 1 and 
2]). Seven days post-infection with IAV, treatment with P4 decreased vasculitis (Fig. 2.1G 
[panels 3 and 4] and H) and edema (Fig 2.1G [panels 5 and 6] and H) as compared to the 
placebo-treated mice (P<0.05). Progesterone improved the outcome of lethal IAV infection by 
limiting lung inflammation and damage, but not virus replication.  
Virus-specific CD8+ T cells are necessary for clearance of IAV but can also contribute to 
immunopathology (197, 303). Although the total numbers of CD8+ T cells increased in all 
females following IAV infection, the total number of CD8+ T cells, the number of IAV-specific 
CD8+ T cells, and the production of IFN-g and TNF-a by virus-specific CD8+ T cells in the 
lungs did not differ between P4- and placebo-treated females (Table 2.1). These data indicate that 
P4 did not affect the cell-mediated antiviral immune response during acute IAV infection.  
Progesterone promotes a repair environment in the lungs during lethal IAV infection  
IAV infection is characterized by the induction of a cytokine storm and excessive 
immunopathology, which leads to tissue damage (265). Damage to the lung endothelium and/or 
epithelium results in vascular leakage into the air spaces, and can be quantified by measuring 
protein concentration in bronchoalveolar lavage (BAL) fluid. Consistent with the 
histopathological findings of increased vasculitis and edema (Fig. 2.1H) following lethal IAV 
infection, treatment of females with P4 decreased the total amount of protein contained in the 
BAL as compared to placebo-treated mice (Fig. 2.2A; P<0.05). Among infected females, 
treatment with P4 also increased cellular proliferation (as measured by Ki67 expression) in the 
lungs as compared to placebo treatment during peak disease (7dpi) (Fig. 2.2B and C; P<0.05). 
Analysis of the expression of Ki67 in the different areas of the lungs revealed greater 
proliferation in several regions of the lungs, but was most pronounced in the epithelial cells lining 
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the airways during IAV infection in P4-treated mice (Fig. 2.2C). The epidermal growth factor, 
AREG, promotes proliferation of epithelial cells and protects mice from excessive pathology 
during IAV infection (279, 280). Analysis of AREG expression during peak disease (7 dpi) 
revealed increased mRNA expression, as well as AREG protein in the bronchioles but not the 
alveoli, in the lungs of P4-treated mice as compared to placebo-treated mice infected with IAV 
(Fig. 2.2D-F, P<0.05).  
Progesterone induces Th17 cells in the lungs of IAV-infected female mice 
Progesterone treatment altered inflammation during IAV infection (Fig. 2.1G and H) and 
induced a repair environment through cellular proliferation and restoration of barrier integrity 
(Fig. 2.2A-C). To further characterize the effect of P4 on inflammatory responses to IAV, a panel 
of 13 cytokines and chemokines was analyzed in the supernatant of whole lung homogenates. As 
expected, following infection with IAV, pulmonary concentrations of IL-1b, TNF-a, IFN-g, and 
IL-12p70 were significantly increased during the first week of infection in all females, regardless 
of P4 treatment (Suppl. Table 2.1; P<0.05). P4 treatment decreased pulmonary production of the 
alarmins IL-13 and IL-33 as compared with placebo treatment during IAV infection (Suppl. 
Table 2.1; P<0.05). The only two cytokines that were significantly increased in P4-treated 
females compared with placebo-treated females during IAV infection were IL-6 and TGF-b (Fig. 
2.3A and B; P<0.05). P4 treatment of IAV-infected mice had no effect on the other canonical 
regulatory protein, IL-10, as compared to placebo treatment (Suppl. Table 2.1).  
Production of TGF-b and IL-6 increases differentiation of Th17 cells. Th17 cells promote 
repair of the gut epithelium (304) and may be similarly involved in orchestrating repair of the 
pulmonary epithelium. To test this hypothesis, populations of CD4+ T cells from mock- and 
IAV-infected mice were enumerated during peak disease (7 dpi). There was no effect of P4 
treatment on total numbers of CD4+ T cells, Th1, Th2, or Treg cells in the lungs at 7 dpi (Table 
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2.1). In contrast, P4 treatment increased the total number of Th17 cells in the lungs during IAV 
infection as compared with placebo treatment (Fig. 2.3C; P<0.05). The cytokine IL-23 is 
necessary for maintenance of Th17 cells and the expression of Il23 mRNA in the lungs was 
increased in P4- compared with placebo-treated females (Fig. 2.3D; P<0.05). Th17 cells exert 
their tissue reparative effects by increasing the production of IL-22 (305). The expression of Il22 
mRNA in the lungs was greater in P4- than placebo-treated females during IAV infection (Fig. 
2.3E; P<0.05). Finally, one surface marker on Th17 cells that is associated with reducing 
inflammation (i.e., regulatory or suppressive Th17 cells) is the ectonucleotidases CD39 (306, 
307). The percentage of Th17 cells that expressed CD39 was significantly increased in P4-treated 
as compared to placebo-treated females during IAV infection (Fig. 2.3F; P<0.05). These data 
indicate that P4 alters the inflammatory milieu of the lungs by promoting a repair environment in 
IAV-infected female mice, with increased numbers of regulatory Th17 cells, elevated expression 
of Il22, and upregulated expression of Areg during lethal IAV infection. 
Progesterone accelerates long-term pulmonary recovery during sublethal IAV infection 
 To further evaluate the role of P4 in lung repair and recovery from IAV infection, P4- 
and placebo-treated female mice were infected with a less pathogenic IAV strain, ma2009, at a 
dose (0.4mLD50) that allowed for monitoring of the mice over a longer duration of time. Similar 
to lethal IAV infection, P4-treated females infected with sublethal IAV showed less hypothermia 
(Fig. 2.4A; P<0.05) and reduced clinical disease (Fig. 2.4B; P<0.05) as compared to placebo-
treated females. Analysis of pulmonary virus titers confirmed that P4 did not alter virus titers or 
clearance of infectious virus over the course of IAV infection (Fig. 2.4C). To determine if P4 
reduced cell death due to IAV infection, LDH levels in the BAL fluid were quantified. Cellular 
damage during IAV infection was not altered by treatment with P4 as compared with placebo 
(Fig. 2.4D). Lung sections were evaluated for markers of inflammation and damage during the 
recovery (14 dpi) and post-recovery (25 dpi) phases of IAV infection. At 14 dpi, but not at 25 dpi, 
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treatment of IAV-infected female mice with P4 decreased the percentage of lesioned areas, 
alveolitis, edema, and cumulative inflammation as compared to placebo-treated mice (Fig. 2.4E-
H, P<0.05). Treatment with P4 significantly increased Ki67 expression in pulmonary cells during 
the recovery phase (14 dpi) of IAV infection as compared with placebo treatment (Fig. 2.4I; 
P<0.05). Based on the observation that P4 treatment promoted lung repair in IAV-infected female 
mice, we evaluated the impact of P4 on overall lung physiology during (14 dpi) and after (25 dpi) 
recovery from sublethal IAV infection by assessing markers of pulmonary function. Lung 
diffusing capacity (DFCO), lung tissue compliance (Crs), and resistance (Rrs) returned to baseline 
faster in P4- than placebo-treated mice infected with IAV (Fig. 2.4J-L, P<0.05). Treatment of 
female mice with P4 reduces inflammation and promotes faster recovery from sublethal IAV 
infection. 
The protective effects of P4 against influenza are mediated by AREG 
Progesterone increased pulmonary AREG expression during lethal IAV infection (Fig. 
2.2D-F) and increased AREG expression is associated with an improved outcome from lethal 
IAV infection (279, 280). In our sublethal IAV model, we were able to measure pulmonary 
expression and production of AREG over a longer duration of time to establish the effects of P4 
on the kinetics of AREG production in females. P4-treatment induced a 30-70 fold greater 
induction of Areg mRNA and higher concentrations of AREG protein in the lungs as compared 
with placebo treatment over the course of IAV infection (Fig. 2.5A and B; P<0.05). Peak 
production of AREG occurred at 9 dpi (Fig. 2.5B), which corresponded with peak disease (Fig. 
2.4A and B) during sublethal IAV infection. To test the hypothesis that reduced AREG 
production in P4-depleted females caused a more severe outcome from IAV, we treated P4-
depleted female mice with recombinant AREG (rAREG) during the course of IAV infection. 
Treatment of P4-depleted mice with rAREG resulted in AREG levels that were comparable to 
those of P4-treated mice at 14 dpi (Fig. 2.5C; P<0.05). Treatment of P4-depleted females with 
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rAREG significantly improved the recovery from IAV infection (Fig. 2.5D and E; P<0.05), with 
reduced inflammation (Fig. 2.5F and G; P<0.05) and improved pulmonary function, including 
lung diffusing capacity (DFCO), lung compliance (Crs), and resistance (Rrs), to levels similar to 
that of P4-treated females (Fig. 2.5H-J; P<0.05). These data suggest that the protective effects of 
P4 on IAV disease may be mediated by an upregulation of AREG.  
The contribution of AREG to P4-mediated protection from IAV infection was further 
determined by using mice that lacked the expression of a functional Areg gene (308). Deletion of 
the Areg gene in female mice (Areg-/-) reversed the protective effects of P4 on the outcome of 
IAV infection (Fig. 2.6A and B; P<0.05). This was accompanied by increased inflammation in 
P4-treated Areg-/- as compared with WT female mice (Fig. 2.6C and D; P<0.05). Improvement 
of pulmonary function in the presence of P4, as measured by lung diffusing capacity (DFCO), 
compliance (Crs), and resistance (Rrs), was also reversed in IAV-infected Areg-/- mice as 
compared with WT mice treated with P4 (Fig. 2.6E-G; P<0.05). Taken together, these data 
indicate that P4 treatment of IAV-infected female mice promotes a pulmonary repair environment 
and restoration of lung function through the induction of AREG. 
Progesterone accelerates wound healing and increases production of AREG by respiratory 
epithelial cells 
 Treatment with P4 induces higher expression of AREG in the lungs of sublethal IAV-
infected females, particularly in the epithelial cells lining the larger airways, as compared with 
placebo-treatment (Fig. 2.7A and B; P<0.05). To assess the contribution of P4 treatment to the 
repair of damaged respiratory epithelia, we used an in vitro model system in which primary, 
differentiated mouse tracheal epithelial cell (mTECs) cultures were mechanically injured. The 
mTECs express the progesterone receptor (Pr), which was upregulated in the presence of P4 (Fig. 
2.7C; P<0.05). Repair of the epithelial cell layer was measured over time to identify the return of 
the transepithelial resistance (TER) to baseline. Following injury, cultures of mTECs treated with 
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P4 returned to baseline TER faster than vehicle-treated cultures (Fig. 2.7D; P<0.05). During 
injury, mTEC cultures treated with P4 produced more AREG mRNA and protein than vehicle-
treated mTECs cultures (Fig. 2.7E and F; P<0.05). These data illustrate that P4 improves 
pulmonary repair and function by increasing AREG production and wound repair in epithelial 
cells.  
Discussion 
Hosts have evolved several mechanisms for overcoming viral infections, such as the 
induction of antiviral defenses that increase resistance to infection, or the activation of regulatory 
and repair responses that increase tolerance to the negative consequences of infection. In the 
present study, P4 significantly protected females during IAV infection by altering inflammation, 
improving pulmonary function, and promoting a pulmonary repair environment, which resulted in 
an earlier recovery. The protective effects of P4 were primarily mediated by the induction of 
AREG during both lethal and sublethal infections. Progesterone did not increase resistance to 
infection in females as demonstrated by the lack of an effect of P4 treatment on virus titers, 
clearance of infectious virus, numbers of Th1 cells, and CD8+ T cell activity in lungs. Instead, P4 
reduced the detrimental consequences of IAV infection in females by increasing their tolerance to 
infection. Several host immunological factors, including TGF-b, Tregs, and regulatory 
populations of CD39+ Th17 cells, are associated with maintaining the balance between protective 
and pathological immune responses during IAV infection. Although P4 treatment had no effect 
on the numbers of Tregs in the lungs during IAV infection, concentrations of TGF-b and IL-6, the 
expression of Il23 and Il22, the number of Th17 cells, as well as the proportion of Th17 cells 
expressing CD39, were increased. Regulatory Th17 cells express the ectonucleotidases CD39 and 
are associated with repair following inflammation and infection (306, 307). Th17 cells also 
promote epithelial cell proliferation and repair in the gut, primarily through the induction of IL-22 
(304). Consequently, treatment of females with P4 increased IL-22, a cytokine that has been 
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shown to mediate regeneration of lung epithelial cells following IAV infection (277). Whether the 
P4-induced increase in regulatory Th17 cells and IL-22 promotes cellular proliferation and repair 
of the lung epithelium during IAV infection by increasing AREG production requires 
consideration. Because P4 directly induced AREG production in respiratory epithelial cells in 
vitro, P4-induced AREG production may occur independent of the reparative effects of regulatory 
Th17 cells in the lungs during IAV infection.   
Progesterone induces repair of epithelial cells in the endometrium and myelin fibers in 
the central nervous system (32, 309). This repair of myelin fibers by P4 (17) is one factor 
mediating how this reproductive hormone mitigates the progression of multiple sclerosis (64). 
Our data show that P4 promotes proliferation of pulmonary cells, including epithelial cells, and 
pulmonary tissue repair. The reparative effects of P4 in the reproductive tract are caused by the 
induction of AREG, which promotes epithelial remodeling in mammary and uterine tissues (295, 
296). In the respiratory tract, AREG is involved in pulmonary tissue remodeling and repair during 
lung injury, asthma, and infection (279, 280, 282-284). Although Areg-gene deficient mice show 
few abnormalities under homeostatic conditions (308), their ability to resolve inflammation or 
infection is severely impaired (282, 294). During IAV infection, administration of rAREG 
protects mice from severe IAV-mediated morbidity by decreasing hypothermia, improving 
pulmonary function, and decreasing protein leakage into the airways (279, 280). The data 
presented are the first report of P4 induction of AREG outside of the reproductive tract and in the 
context of infection. The effect of other reproductive hormones on AREG expression, including 
differential expression between males and females, warrants further study.  
AREG is produced primarily by epithelial cells (287), but type 2 innate lymphoid cells 
(ILC2) and Tregs have also been shown to produce AREG during IAV infection and contribute to 
the repair during resolution of infection (279, 280, 287, 288). Because each of these cell type 
express progesterone receptors (13, 310), each is a potential producer of AREG in response to P4 
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treatment. Our in vivo and in vitro data suggest that respiratory epithelial cells are a predominant 
source of P4-induced AREG. Following IAV infection, AREG expression was predominantly 
localized to the bronchiolar epithelial cells, and P4 treatment of isolated mTECs increased AREG 
production following mechanical damage. Furthermore, P4-treatment did not activate markers of 
ILC2s, including IL-13 and IL-33 production, or increase numbers of Tregs in the lungs during 
infection, suggesting that the induction of AREG in response to P4 may not be occurring in these 
immune cell populations.  
Recovery following IAV infection is generally defined as a return of body temperature or 
body mass back to homeostatic levels (311). In this study, however, we showed that pulmonary 
pathology and impaired pulmonary function persisted after measures of overall health, including 
hypothermia and clinical disease, returned to baseline. Furthermore, the impact of IAV infection 
was observed long after infectious virus had been cleared from the lungs. Recovery following 
IAV infection extended beyond 21 dpi and should be defined not only by reduced morbidity, but 
also by restored pulmonary function, both of which were expedited by P4 treatment in females.  
Progesterone concentrations fluctuate naturally during the female life span, with 
moderate concentrations during the menstrual cycle, high concentrations during pregnancy, and 
low concentrations following menopause. Progesterone is also used exogenously by over 100 
million women worldwide in P4-based hormonal contraceptives, by post-menopausal women 
taking hormonal replacement therapy, and by both men and women in the treatment of cancer, 
osteoporosis, and brain injury (4, 8). Prior to this study, the health consequences of P4-based 
therapies in acute respiratory infection had not been characterized.  We have demonstrated that 
AREG, which is a significant factor that induces tissue repair and recovery from infectious 
diseases, is regulated by P4 during both lethal and sublethal IAV infection. The data presented 
provide critical mechanistic information about how P4 and possibly synthetic P4 analogues affect 
women’s health outside of the reproductive tract. Contraceptives that contain P4 are listed as an 
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essential medication by the WHO, being a safe and effective method for improving health 
outcomes in women, including those living with HIV (289). During outbreaks of infectious 
diseases that harm pregnant women and their fetuses (e.g., the current Zika outbreak), the WHO 
recommends increased use of hormonal contraceptives, which according to our data could have 
additional beneficial consequences on the outcome of other infectious diseases.  
  
	   47  
Material and Methods 
Ethics statement  
All experiments were performed in compliance with the standards outlined in the National 
Research Council’s Guide to the Care and Use of Laboratory Animals. The animal protocol 
(M015H236) was reviewed and approved by the Johns Hopkins University Animal Care and Use 
Committee. All efforts were made to minimize animal suffering.  
Animals  
Adult (7–8 weeks old) female C57BL/6 mice were purchased from NCI Frederick. Areg
+/- 
(C57BL/6 129 Sv) mice were kindly provided by Dr. Marco Conti (University of California San 
Francisco) and bred to obtain Areg-/- and Areg+/+ female littermates. Mice were housed 5 per 
microisolator cages under standard BSL-2 housing condition with food and water ad libitum.  
Surgical procedures  
At 8–12 weeks of age, mice were anesthetized with an intramuscular injection of ketamine (80 
mg/kg) and xylazine (8 mg/kg) cocktail and ovaries were removed bilaterally as previously 
described (222). All animals were given two weeks to recover prior to infection. Recombinant 
amphiregulin (10µg; R&D) was administered intraperitoneally every other day using saline as the 
vehicle.  
Hormone replacement and quantification  
Ovariectomized (ovx) mice were assigned to receive subcutaneous implants of placebo (-P4) or 
15 mg progesterone (+P4) 21-day release pellets (Innovative Research of America) prior to IAV 
inoculation. Circulating concentrations of P4 were assessed from plasma using ether extraction 
and radiolabelled immunoassay, with P4 antibody (MP Biomedicals) and tracer 3H-P4 (American 
Radiolabeled). Uterine horns were removed at several time-points upon euthanasia of mice and 
wet weight was quantified as a bioassay for P4.  
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Virus infection and quantification  
Mouse-adapted influenza A viruses, A/Puerto Rico/8/34 (PR8; H1N1) provided by Dr. Maryna 
Eichelberger at the Food and Drug Administration (FDA) and A/California/04/09 (ma2009; 
H1N1) generated by Dr. Andrew Pekosz from a published sequence (251), were used in these 
studies. Mice were anesthetized and inoculated intranasally with 30 µl of DMEM (mock) or 
H1N1 virus (1.78 50% mouse lethal dose (MLD50) for PR8 and 0.4 MLD50 for ma2009). 
Clinical disease scores for IAV-infected mice were based on four parameters, with one point 
given for each of the following: dyspnea, piloerection, hunched posture and absence of an escape 
response. For virus quantification, log10 dilutions of lung homogenates (starting at 10
-1) were 
plated onto a monolayer of MDCK cells in replicates of 6 for 4–6 days. Cells were stained with 
naphthol blue black (Sigma Aldrich) and scored for cytopathic effects. The 50% tissue culture 
infectious dose (TCID50) was calculated according to the Reed-Muench method.  
Cytokine and chemokine quantification  
Snap-frozen lung tissue was homogenized in DMEM supplemented with 1% 
penicillin/streptomycin and 1% L-glutamine (Invitrogen) and centrifuged to remove cellular 
debris. Supernatants were harvested to measure IL-1β, TGF-β, IL-4, IL-5, IL-13, IL-17, IL-33, 
and AREG by ELISA (R&D Systems and BD Biosciences) and CCL-2, IL-12(p70), TNF-α, IFN-
γ, IL-6 and IL-10 with the mouse inflammation cytometric bead array (BD Biosciences) 
according to the manufacturer’s protocols.  
Real time reverse transcription PCR  
Snap-frozen lung tissue or mTECs were homogenized in TRIzol and RNA was purified by 
chloroform extraction. RNA concentration and purity was measured using a NanoDrop 
(ThermoFisher Scientific). The RNA concentration in each sample was standardized to 1 µg 
using RNAse-free water. Reverse transcription was carried out using the iScript cDNA synthesis 
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kit (Biorad) according to the manufacturer’s protocol. Pre-designed Il23 
(Mm.PT.58.10594618.g), Il22 (NM_016971.2), Areg (Mm.PT58.31037760), Gapdh 
(Mm.PT.39a.1) and Pr (Mm. PT.58.10254276) PrimeTime Primers were purchased from 
Integrated DNA Technologies. Semi-quantitative RT-PCR was performed in 96-well optical 
reaction plates using the SsoFast EvaGreen Supermix (Biorad) on the StepOnePlus RT-PCR 
system (Applied Biosystems). Gene expression was normalized to Gapdh and mock-infected 
samples or wells with no injury using the ΔΔCt method.  
Flow cytometry analyses of T cells  
Lungs were excised and single-cell suspensions were generated following red blood cell lysis. 
Total viable cells were determined using a hemocytometer and trypan blue (Invitrogen) exclusion 
and resuspended at 1x106 cells/ml in RPMI 1640 (Cellgro) supplemented with 10% FBS (Fisher 
Scientific) and 1% penicillin/streptomycin. For IAV-specific T cells enumeration, cells were 
cultured for 5h with IAV peptide antigen (CD8:NP366-374, or CD4: HA211-255, NP311-325, 
respectively) (ProImmune) in media containing Brefeldin A (GolgiPlug, BD) The viability of 
cells was determined by fixable Live/Dead violet viability dye (Invitrogen) and Fc receptors were 
blocked using anti-CD16/32A. The T cell populations were stained with the following antibodies: 
PerCP-Cy5.5 conjugated anti-CD4 (RM4-5)A, PerCP-Cy5.5 conjugated anti-CD8 (53–6.7)A, 
FITC conjugated anti-CD25 (7D4)A, PE conjugated DbNP366-374 tetramer (NIH Tetramer Core 
Facility), FITC conjugated anti-CD4 (RM4-5)B, APC conjugated anti-CD3 (17A2B, and PerCP-
eFluor 710 conjugated anti-CD39 (24DMS1)B. Intracellular staining with PE conjugated anti-
TNF-α(MP6-XT22)A, FITC conjugated anti-IFN-γ (XMG1.2)A, PE conjugated anti-IL-4 
(11B11)A, and PE conjugated anti-IL-17 (TC11-1810)A, was performed following 
permeabilization and fixation with Cytofix/Cytoperm and Perm/Wash bufferA. Intracellular 
staining with PE-conjugated Foxp3 (MF23)A was performed following fixation and 
permeabilization with a Foxp3 staining buffer setA. Data were acquired using a FACS Cali- bur 
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(Cellquest Software) and analyzed using FlowJo (Tree Star, Inc.). Total cell counts were 
determined by multiplying each live cell population percentage by the total live cell counts 
acquired prior to staining by trypan blue exclusion counts on a hemocytometer. All reagents were 
purchased from BD BiosciencesA or eBioscienceB unless stated otherwise.  
Histopathology and immunohistochemistry  
Lungs were inflated, fixed in Z-fix (Anatech), embedded in paraffin, cut into 5µm sections, and 
mounted on glass slides. Slides were stained with hematoxylin and eosin (H&E) and used to 
evaluate lung inflammation. Histopathological scoring was performed by a single blinded 
veterinary pathologist on a scale from 0–3 (0, no inflammation; 1, mild inflammation; 2, 
moderate inflammation; and 3, severe inflammation) for the following parameters: bronchiolitis, 
alveolitis, vasculitis, perivasculitis, necrosis, consolidation, and edema (155, 312). The sum of 
these parameters represents the cumulative inflammation score. The percentage of lesioned areas 
within each tissue section was also evaluated. Histopathological slides were deparafinized with 
xylene and rehydrated in graded ethanol. Heat-induced antigen retrieval with citrate buffer was 
performed and slides were blocked with 10% normal serum prior to overnight primary antibody 
incubation. For Ki67, rabbit anti-Ki67 (1/200; Abcam) was used, detected with the EXPOSE 
rabbit specific HRP/DAB detection kit (Abcam), counterstained with Hematoxylin and slides 
were mounted using Permount (Fisher). For immunofluorescence, anti-AREG (1/ 100; R&D) and 
anti-β-tubulin IV (1/100; BioGenex) were used and detected with appropriate secondary 
antibodies (1/400) conjugated to AF-555 (Thermo) and AF488 (Molecular probes). Slides were 
then treated against autofluorescence using 0.3% Sudan Black B (Sigma) in 70% ethanol and 
mounted using anti-fade medium containing DAPI (ProLong Gold from Cell Signaling 
Techonology). Images were taken using a Nikon Eclipse E800 (for H&E and Ki67 stains) or a 
Zeiss AxioImager M2 (for immunofluorescence) and analyzed using ImageJ (NIH).  
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Bronchoalveolar lavage  
Mice were euthanized by cervical dislocation and the lungs were lavaged twice with 0.5ml of a 
0.9% saline solution. Bronchoalveolar lavage (BAL) fluid was centrifuged at 500g for 10 minutes 
to remove cells and debris and the supernatant was collected to quantify total protein leak- age 
into the airway using a BCA assay (Pierce). Cell lysis and damage was analyzed from BAL fluid 
by measuring lactate dehydrogenase leakage using an LDH assay kit (Sigma).  
Pulmonary function phenotyping  
Lung Diffusing Capacity (DFCO) quantifies the ability of the lung to exchange gas, which is its 
primary function. Diffusing capacity is simple and quick to measure in humans and mice, and it 
decreases with nearly all lung pathologies, including viral infections. At the selected time points, 
a cohort of mice was anesthetized via an IP injection of ketamine–xylazine (100 mg/ kg–10 
mg/kg), and then an 18-g stub needle was secured in the trachea. 0.8 mL of a gas mixture 
containing 0.3% neon, 0.3% CO in room air was quickly injected into the lungs, held for 9 s, then 
quickly withdrawn. This post breathold sample was then injected into a desktop gas 
chromatograph (Inficon, Micro GC model 3000A) to measure the concentrations of Ne and CO. 
The DFCO in mice is analogous to the DLCO in humans, and is calculated as 1−(CO9/ 
COc)/(Ne9/Nec), where subscripts c and 9 refer to the calibration gas injected and the gas from 
the 9 s exhaled sample. DFCO is thus a dimensionless variable which varies between 0 and 1, and 
is used to detect the loss and recovery of lung function after the viral infections used in this study 
(313). 
Lung mechanics: After the DFCO is measured, the tracheostomy cannula was then connected to a 
Flexivent system (Scireq). Ventilation was accomplished at a rate of 150 breaths/ minute and a 
tidal volume of 10 ml/kg with a PEEP of 3 cm H2O. A deep inspiration to 30 cmH2O was done, 
and 1 minute later the respiratory resistance (Rrs) and compliance (Crs) were measured (314). 
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Increased resistance reflects increased difficulty in dynamically moving air into the lung and 
decreased compliance reflects increased difficulty in expanding the lung parenchyma.  
Mouse tracheal epithelial cell (mTEC) cultures  
For mTEC cultures, tracheas were obtained from 7–9 week old C56BL/6 female mice, digested 
overnight in 0.3% pronase, and enriched by depleting fibroblasts as previously described (315, 
316). The mTECs were cultured at a density of 2.22x105 cells/ml on collagen-coated 24-well 
transwell plates for 7 days (i.e., until the cultures reached a transepithelial resistance above 1000 
Ω· cm2) and apical medium was removed to create an air-liquid interface for 14 days to induce 
differentiation as described previously (316). Cells were pre-treated for 24 h with basolateral 
media containing vehicle (100% ethanol) or 100nM P4 (Sigma), and injured by scratching the 
cell layer with a 10ul XL pipette tip, or left uninjured, and loose cells were removed by washing 
with media. Transepithelial cell resistance (TER) was measured prior to injury, immediately after, 
and every 12h for 48 h by adding 100µl of warm TEC basic media to the apical chamber. New 
media with vehicle or P4 was added every 24h. Every 12h, basolateral media was sampled and 
analyzed for AREG expression by ELISA (R&D) according to the manufacturer’s protocol. Cells 
were harvested in Trizol every 12h and analyzed by RT-PCR as described above.  
Statistical analyses  
A power and sample size calculation was used to confirm group sizes for a power of 0.8 and 
contributes to differential sample sizes for some dependent measures. Repeat measures were 
analyzed with a multivariate analysis of variance (MANOVA) followed by planned comparisons. 
Discrete measures were analyzed with T-tests or two-way ANOVA followed by the Tukey 
method for pairwise multiple comparisons. Survival was analyzed using a Kaplan Meyer survival 
curve followed by a log-rank test. Mean differences were considered statistically significant if 
P<0.05.  
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Figure and table legends 
Figure 2.1. Progesterone (P4) protects adult female mice against lethal IAV infection. Adult 
female mice were ovariectomized, treated with placebo (-P4) or exogenous P4 (+P4), and 
inoculated with lethal IAV or mock-infected. Serum was collected at 3, 5, 7, and 21 days post-
inoculation (dpi) and P4 concentrations (mock n = 5, IAV n = 20–22 [i.e., n = 5–7 per dpi]) were 
analyzed by radioimmunoassay, and uterine horns (mock n = 13, IAV = 35–38 i.e., n = 12–14 dpi 
time-point) were weighed (A). Lungs were harvested at days 3, 5, or 7 dpi and mRNA expression 
of the progesterone receptor (Pr) was measured and normalized to GAPDH and mock-infected 
animals using the ΔΔCt method (B). Values for each measure (A and B) did not differ between 
dpi and are shown as aggregates. Mice (-P4 n = 20, +P4 n = 10) were monitored daily for changes 
in rectal body temperature (C) and survival (D) for 21 dpi. Infectious virus titers in the lungs were 
measured at 3, 5, or 7 dpi (E; n = 8-10/treatment/dpi). The correlation between changes in body 
temperature and virus titers at 7dpi, as a measure of disease tolerance, was quantified using a 
linear regression model (F; n = 12/treatment). H&E stained lung sections collected at 7dpi from 
mock-infected (G, panel 1 and 2) and IAV-infected females (G, panels 3–6) were scored for 
inflammation. Alveolitis (G panel 3 and 4, indicated by black triangles) and edema are shown (G 
panels 5 and 6, indicated by black stars), as well as corresponding histopathogical scores on a 
scale from 0–3 (H, n = 3/treatment, 10 fields/animal, 10X magnification). Data represent means ± 
SEM from two independent experiments and significant differences are represented by asterisks 
(*).  
Figure 2.2. Progesterone (P4) treatment promotes barrier integrity, cellular proliferation, 
and induction of amphiregulin (AREG) in the lungs of IAV- infected female mice. Adult 
female mice were ovariectomized, treated with placebo (-P4) or exogenous P4 (+P4), and 
inoculated with lethal IAV or mock-infected. At peak disease (7dpi), bronchoalveolar lavage 
(BAL) fluid or whole lungs were harvested or fixed for histology. Total protein content in the 
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BAL was measured by BCA assay (A). Cellular proliferation was assessed at 7 dpi using the 
marker Ki67 in paraffin-embedded lung tissue sections; sections were counterstained with 
hematoxylin; and arrows indicate examples of Ki67+ cells (C). The percentages of Ki67+ cells 
were analyzed and quantified using ImageJ (B and C; 10X magnification). Areg mRNA 
expression was quantified and normalized to Gapdh and to mock-infected controls (D). The 
percentages of AREG+ cells (red) in bronchioles and alveolar airspace were analyzed using 
immunofluorescence and quantified using ImageJ (E; n = 20 fields/treatment). Representative 
images of bronchioles (10X magnification) and focused areas (40X magnification) with epithelial 
cells (β- tubulin+ cells, in green) are shown (F). Bars represent means ±SEM from two or three 
independent experiments. Significant differences are represented by an asterisk (*) (mock: n = 6; 
IAV: n = 10–12).  
Figure 2.3. Progesterone (P4) treatment induces regulatory Th17 cells in the lungs of IAV-
infected female mice. Adult female mice were ovariectomized, treated with placebo (-P4) or 
exogenous P4 (+P4), and inoculated with lethal IAV or mock-infected. At peak disease (7 dpi), 
supernatant from whole lung homogenates was used to quantify IL-6 (A) and TGF-β (B). The 
total numbers of Th17 (C) cells were measured by flow cytometry in lung single-cell suspensions 
stimulated ex vivo with IAV-specific antigen (DbHA211-255 and DbNP311-325) in presence of 
BFA. The expression of Il23 and Il22 was analyzed in lung tissue and normalized to GAPDH and 
to mock-infected controls using the ΔΔCt method (D and E). Expression of CD39 was evaluated 
by flow cytometry on Th17 cells (F) from lung single-cell suspensions. Bars represent means 
±SEM from two or three independent experiments. Significant differences are represented by an 
asterisk (*) (mock: n = 6; IAV: n = 10–12).  
Figure 2.4. Progesterone (P4) reduces inflammation and improves pulmonary function 
during sublethal IAV infection. Adult female mice were ovariectomized, treated with placebo (-
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P4) or exogenous P4 (+P4), and inoculated with a sublethal dose of IAV or mock-infected. 
Females (n = 23-25/treatment) were monitored daily for changes in rectal body temperature (A) 
and clinical disease (B) for 21 dpi. Infectious virus titers (C) and cell necrosis (D) were measured 
3, 5, 7, 9 and 14 dpi (n = 5–10 per dpi). Percentage of lesioned areas (E), alveolitis scores (F), 
edema scores (G), and cumulative inflammation scores (H) were quantified in H&E stained lung 
sections at 14 and 25 dpi. The numbers of proliferating of Ki67+ cells were analyzed at 14 and 25 
dpi and quantified using ImageJ (I) (n = 3-5/treatment/dpi with 10 fields per animal). Pulmonary 
function tests, measuring lung diffusing capacity (DFCO; J), lung tissue compliance (Crs; K), and 
resistance (Rrs; L), were performed at 14 and 25 dpi with the dotted line representing the average 
value (mean ±SEM) for mock-infected mice (n = 7-10/treatment/dpi). Data represent means 
±SEM from 2–3 independent experiments and significant differences are represented by asterisks 
(*).  
Figure 2.5. Progesterone (P4) increases amphiregulin (AREG) expression and 
administration of recombinant AREG protects P4-depleted female mice against IAV 
infection. Adult female mice were ovariectomized, treated with placebo (-P4) or exogenous P4 
(+P4), and inoculated with a sublethal dose of IAV or mock-infected. The expression of 
amphiregulin (Areg) mRNA (A) and protein concentrations (B) in the lungs were quantified at 3, 
5, 7, 9 and 14 dpi (n = 8-10/treatment/dpi). Gene expression was normalized to Gapdh and mock-
infected controls using the ΔΔCt method. Ovariectomized mice were treated with placebo (-P4), 
placebo and recombinant amphiregulin (-P4 +rAREG), or P4 (+P4) and inoculated with a 
sublethal dose of IAV. To confirm AREG replacement, pulmonary concentrations of AREG were 
measured at 14 dpi (C). Mice were monitored daily for changes in body temperature (D) and 
clinical disease (E) (n = 9-10/treatment). H&E stained lung sections collected at 14 dpi were 
scored for inflammation as a cumulative score of perivasculitis, vasculitis, bronchiolitis, 
alveolitis, edema, consolidation, and necrosis (F). Representative images of overall inflammation 
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(2X magnification) and focused areas (10X magnification) with cellular infiltration and edema 
are shown (G) (n = 3-5/treatment, with 10 fields per animal). Pulmonary function tests were 
performed at 14 dpi and lung diffusing capacity (DFCO; H), lung compliance (Crs; I), and 
resistance (Rrs; J) were measured (n = 8-10/treatment). The dotted lines represent the value 
(means ±SEM) for mock-infected mice and bars and circles represent means ±SEM for IAV-
infected mice from 2 independent experiments, with significant differences represented by 
asterisks (*).  
Figure 2.6. Deletion of amphiregulin (Areg) reverses the protective effects of progesterone 
(P4) during IAV infection. Female Areg-/- or WT littermates were ovariectomized, treated with 
P4, inoculated with a sublethal dose of IAV or mock-infected, and monitored daily for changes in 
body temperature (A) and clinical disease (B) (n = 15/treatment). At 14 dpi, inflammation was 
scored from H&E stained lung sections for inflammation as a cumulative score of perivasculitis, 
vasculitis, bronchiolitis, alveolitis, edema, consolidation and necrosis (C). Representative images 
of overall inflammation (2X magnification) and focused areas (10X magnification) with cellular 
infiltration and edema are shown (D) (n = 5/treatment, with 10 fields per animal). Pulmonary 
function tests were performed at 14 dpi and lung diffusing capacity (DFCO; E), lung compliance 
(Crs; F), and resistance (Rrs; G) were measured (n = 10-12/ treatment). The dotted lines represent 
the value (means ±SEM) for mock-infected Areg-/- mice and bars and circles represent means 
±SEM for IAV- infected mice from 2 independent experiments, with significant differences 
represented by asterisks (*).  
Figure 2.7. Progesterone induces amphiregulin (AREG) and accelerates wound healing in 
respiratory epithelial cells. Adult female mice were ovariectomized, treated with placebo (-P4) 
or exogenous P4 (+P4), and inoculated with a sublethal dose of IAV. Animals were euthanized at 
14 dpi and lungs were fixed for histology (n = 5/treatment). AREG expression (in red) was 
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assessed in epithelial cells (β-tubulin+ cells, in green) using immunofluorescence in different 
areas of the lung tissue (A). Representative images of bronchioles (10X magnification) and 
focused areas (40X magnification) are shown. The percentages of AREG+ cells in bronchioles 
and alveolar airspace were analyzed and quantified using ImageJ (B; n = 20 fields/treatment). 
Mouse tracheal epithelial cell (mTEC) cultures were treated with vehicle (EtOH) or P4 and 
injured or left intact. Relative expression of progesterone receptor (Pr) mRNA was measured 
every 12 h for 48h (C). Transepithelial resistance (TER) (D), AREG production (E), and Areg 
mRNA relative expression (F) were measured every 12h for 48h (n = 10/treatment/time-point). 
Areg and Pr mRNA expression was normalized to Gapdh and to uninjured controls using the 
ΔΔCt method (n = 5/treatment/time-point). Bars or squares represent means ±SEM from 2–3 
independent experiments, with significant differences represented by asterisks (*).  
Table 2.1: Total numbers of CD4+ and CD8+ T cells in lung single cell suspensions from 
IAV-infected ovariectomized female mice treated with placebo (-P4) or progesterone (+P4) 
at 7dpi. Data are presented as the mean ± SEM from four independent experiments (CD8+ T 
cells: n=6-8/treatment; CD4+ T cells: n=10-12/treatment) and were analyzed by T-tests. 
Supplemental Table 2.1. Cytokine and chemokine concentrations in lung homogenates from 
ovariectomized female mice treated with placebo (-P4) or progesterone (+P4).  Adult female 
mice were ovariectomized, treated with placebo (-P4) or exogenous P4 (+P4), and inoculated 
with lethal IAV or mock-infected. Supernatant from whole lung homogenates was used to 
quantify cytokines at 3,5 and 7dpi. Data are presented as the mean ± SEM in pg/ml (a) or ng/ml 
(b) from two independent experiments (n=8-10/treatment/dpi). Data were analyzed with two-way 
ANOVA followed by Tukey tests, with significant differences compared with –P4 females at an 
individual time-point represented by an asterisk (*), significant differences within a treatment 
group at 7 or 5dpi compared with day 3 represented by a plus (+) P>0.05. 
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Table 2.1  
Total numbers of cells -P4 +P4 
CD8+ T cells (x105) 2.43±0.52 1.91±0.29 
NP366-374 CD8+ T cells (x104) 5.7±0.49 3.28±0.68 
IFN-γ+ CD8+ T cells (x104) 1.37±0.6 1.84±0.65 
TNF-α CD8+ T cells (x104) 7.44±2.2 5.42±1.76 
Total CD4+ T cells (x105) 4.35±0.73 3.46±0.52 
IFN-γ+ CD4+ T cells (x104) 2.96±0.91 3.45±1.22 
IL4+ CD4+ T cells (x104) 2.62±0.75 5.14±1.76 
Foxp3+ CD4+ T cells (x104) 5.58±2.28 3.47±1.66 
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Supplemental Table 2.1 
  Days Post-Infection 
Cytokine Treatment 3 5 7 
IL-1βa - P4 928.7±135.2 1308.4±129.7 710.7±110.9 
 +P4 1253.9±96.4 1576.1±227.4 1022.9±202.6 
TNF-αa - P4 162.7±84.4 235.4±16.2 313.0±21.0 
 +P4 140.3±7.4 279.9±20.0 371.3±18.8* 
IL-6a - P4 978.3±119.7 1339.2±107.4 700.2±92.5 
 +P4 1207.9±2* 1478.7±177.3* 949.0±122.8* 
IFN-γa - P4 82.7±6.4 67.7±4.9 3889.3±457.7+ 
 +P4 56.6±3.65 104.2±13.6 3092.4±399.3+ 
IL-12p70a - P4 6.6±0.4 10.5±0.9+ 16.4±1.2+ 
 +P4 5.6±0.8 8.4±1.5+ 17.5±1.6+ 
IL-4a - P4 37.6±10.6 71.6±23.6 52.9±26.5 
 +P4 28.6±4.1 30.3±6.4 11.8±3.8 
IL-5a - P4 27.9±5.7 57.3±8.9 66.6±9.3 
 +P4 42.7±13.9 48.6±9.9 110.1±10.4* 
IL-13a - P4 461.6±27.2 243.2±56.3 184.3±48.6 
 +P4 191.6±42.0* 189.7±40.1 309.7±90.4 
IL-33 b - P4 57.6±8.3 41.8±9.0 21.3±5.6 
 +P4 41.0±9.9 28.7±5.6 16.9±3.4 
IL-10a - P4 25.2±4.5 24.2±3.1 158±17.9+ 
 +P4 26.9±4.4 21.1±2.7 178.5±25.7+ 
TGF-β b - P4 8299.0±1367.0 5953.0±469.0 7433.0±674.0 
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Abstract 
In addition to their intended use, progesterone (P4)-based contraceptives promote anti-
inflammatory immune responses, yet their effects on the outcome of infectious diseases, 
including influenza A virus (IAV), are rarely evaluated. To evaluate their impact on immune 
responses to sequential IAV infections, adult female mice were treated with placebo or one of two 
progestins, P4 or levonorgestrel (LNG), and infected with mouse adapted (ma) H1N1 virus. 
Treatment with P4 or LNG reduced morbidity during primary H1N1 infection as compared to 
placebo treatment. In serum and bronchoalveolar lavage fluid, total anti-IAV IgG and IgA titers 
and virus neutralizing antibody titers, but not hemagglutinin stalk antibody titers, were lower in 
progestin-treated mice as compared with placebo-treated mice. Females were challenged six 
weeks later with either a maH1N1 drift variant (maH1N1dv) or maH3N2 IAV. Protection 
following infection with the maH1N1dv was similar among all groups. In contrast, following 
challenge with maH3N2, progestin treatment reduced survival as well as numbers and activity of 
H1N1- and H3N2-specific memory CD8+ T cells, including tissue resident cells, compared with 
placebo treatment. In contrast to primary IAV infection, progestin treatment increased 
neutralizing and IgG antibody titers against both challenge viruses compared with placebo 
treatment. While the immunomodulatory properties of progestins protected naïve females against 
severe outcome from IAV infection, it made them more susceptible to secondary challenge with a 
heterologous IAV, despite improving their antibody responses against a secondary IAV infection. 
Taken together, the immunomodulatory effects of progestins differentially regulate the outcome 
of infection depending on exposure history.  
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Importance 
The impact of hormone-based contraceptives on the outcome of infectious diseases 
outside of the reproductive tract is rarely considered. Using a mouse model, we have made the 
novel observation that treatment with either progesterone or a synthetic analog found in hormonal 
contraceptives, levonorgestrel, impacts sequential influenza A virus infection, by modulating 
antibody responses and decreasing memory CD8+ T cells. Progestins reduced antibody responses 
during primary H1N1 virus infection, but increased antibody titers following a sequential 
infection with either a H1N1 drift variant or a H3N2 virus. Following challenge with a H3N2 
virus, female mice treated with progestins experienced greater mortality with increased 
pulmonary inflammation and reduced numbers and activity of CD8+ T cell. This study suggests 
that progestins significantly affect adaptive immune responses to influenza A virus infection, with 
their effect on influence outcome depending on exposure history.  
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Introduction 
Adults worldwide are exposed to multiple influenza viruses and viral antigens during 
their lifetime both through natural infection and vaccination. In the United States, since 2010, 
vaccination has been recommended for all individuals ages 6 months and older (317). By six 
years of age, all children have been exposed to at least one influenza virus, with infections with 
novel antigenically distinct viruses occurring every 5-10 years (263, 318). By adulthood, most 
individuals are no longer influenza-naïve, which is rarely considered in animal models of 
influenza A virus (IAV) pathogenesis.  
Protective immune responses to sequential IAV infections include cross-reactive 
antibodies, including broadly neutralizing antibodies which target the conserved stalk region of 
the hemagglutinin (HA) antigen and CD8+ T cell responses, the latter being the primary 
mechanism of cross-protection against heterosubtypic influenza strains, as CD8+ T cells can 
recognize conserved viral proteins, including the nucleoprotein (180, 204, 205). In addition to 
circulating memory T cells and T central memory (TCM) cells that traffic through the lymph 
nodes, tissue-resident memory (TRM) cells promote local and immediate protection in the lungs 
with the ability to expand rapidly, kill virus-infected cells, recruit circulating memory T cells, and 
release cytokines, resulting in TRMs being indispensable for heterosubtypic protection (206-208). 
Several factors, including the sex, age, and reproductive status of the host can influence 
adaptive immune responses and the outcome of IAV infection (211, 319, 320). During IAV 
infection, sex steroids, in general, and progesterone (P4), in particular, can alter the functioning of 
immune cells and respiratory epithelial cells to reduce pulmonary inflammation, improve 
pulmonary repair and function, and cause faster recovery from primary infection with IAV (131, 
320, 321). Data from our lab (131) and others (33, 34, 39, 53, 60) illustrate that P4 has broad anti-
inflammatory properties, resulting in reduced activity of NK and T cells, lower antibody 
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responses, greater concentrations of TGF-b, and increased numbers and activity of regulatory T 
cells and regulatory Th17 cells.  
In addition to natural exposure to P4 through ovarian and placental production during 
reproductive cycles and pregnancy, respectively, females can be exposed to synthetic forms of P4 
(i.e., progestins) through the use of hormone-based contraceptives, all of which contain some 
form of progestin (4). It is estimated that 88% of all adult women in the US have been exposed to 
progestins in some form of contraceptives (20). Progestins, such as levonorgestrel (LNG), are 
more commonly used in contraceptives than P4 because they bind to the progesterone receptor 
with greater affinity, have a longer half-life, and cause fewer side-effects (19). Despite the broad 
use of progestins and their known anti-inflammatory properties, their effects on viral infections at 
mucosal sites outside of the reproductive tract have not been adequately explored.  
The goal of this study was to evaluate the effects of both P4 and LNG on adaptive 
immune responses and the outcome of sequential infection with an IAV drift variant or 
heterosubtypic IAV.  We hypothesized that, similar to the effects of P4 treatment in 
ovariectomized mice, exposure to either P4 or LNG in ovary-intact mice would improve the 
outcome of a primary IAV infection in immunologically naïve females by reducing inflammation 
and adaptive immune responses that contribute to immune-mediated pathology (131). Following 
secondary challenge with either a drift variant or heterosubtypic strain of IAV, we speculated that 
the reduced adaptive immune responses to the primary infection, while beneficial for recovery 
from the primary infection, may cause reduced protection against a subsequent infection. Our 
findings demonstrate that following treatment with either P4 or LNG, females were better 
protected from a primary IAV infection, despite generating lower antibody and memory CD8+ T 
cell responses. Following secondary infection with a heterosubtypic, but not a drift variant IAV 
virus, females treated with either P4 or LNG suffered a worse disease outcome from infection, 
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which was likely mediated by insufficient memory T cell responses as opposed to antibody 
responses from the primary infection.   
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Results 
Progesterone and levonorgestrel protect against primary IAV infection, but reduce systemic 
and pulmonary antibody responses against IAV 
Adult female mice were treated with subcutaneous placebo, P4, or LNG pellets, which 
delivered a continuous dose of hormone over the course of 60 days, and infected with a low dose 
of ma2009 H1N1 virus. Similar to previously published results in ovariectomized female mice 
(131), treatment of ovary-intact females with P4 reduced morbidity following IAV infection, by 
decreasing body mass loss, hypothermia, and clinical disease as compared to placebo treatment 
(Fig. 3.1A and B and data not shown; P<0.05). One of the most common progestins (i.e., 
synthetic analog of P4) used in hormonal contraceptives is LNG, which signals through the 
progesterone receptor with greater affinity than P4 (11). Similar to P4 treatment, mice treated 
with LNG and infected with a low dose of ma2009 H1N1 virus had less morbidity than placebo-
treated females during infection, including reduced body mass loss, hypothermia, and clinical 
signs (Fig. 3.1A and B and data not shown; P<0.05).  
Serum titers of anti-ma2009 IgG antibodies were measured at 14, 21, 28, and 35 days 
post-inoculation (dpi) and did not differ between placebo- and P4-treated females, but were 
transiently lower at 21 dpi following LNG treatment (Fig. 3.1C; P<0.05). Serum titers of 
neutralizing antibodies measured at 14, 21, 28, and 35 dpi against the ma2009 virus were 
significantly reduced in females with P4 (at 21 dpi) or LNG (at 14 and 35 dpi) treatment as 
compared to placebo (Fig. 3.1D; P<0.05). Progestins reduced neutralizing antibody responses, 
however, titers at 35 dpi remained around the 1/640 dilution, which is high enough to protect 
mice against a homologous challenge (218). Antibody titers in the bronchoalveolar lavage (BAL) 
fluid were also analyzed at 14, 21 and 28 dpi to assess the mucosal immune response at the local 
site of infection. Both anti-ma2009 IgA and neutralizing antibody titers against ma2009 in the 
BAL were reduced in females treated with either P4 (at 28 dpi) or LNG (at 21 and 28 dpi) as 
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compared to females treated with placebo (Fig. 3.1E and F; P<0.05). In summary, P4 and, to a 
greater extent, LNG protect females against IAV infection, but significantly reduce systemic and 
local antibody production during a primary infection. 
Protection against an H1N1 drift variant and hemagglutinin stalk antibody responses are 
not affected by treatment with progestins 
To assess whether the P4 and LNG-induced reduction in serum and, to a greater extent, 
BAL antibody titers (Fig. 3.1C-F) could impact the outcome of sequential infection with a 
closely related H1N1 virus, female mice were treated with P4, LNG, or placebo, inoculated with 
ma2009 H1N1 virus, and then challenged six weeks later with a H1N1 ma2009 drift variant 
(ma2009dv) which contained a mutation at position 166 in the HA head domain (K166Q) (145) 
(Fig. 3.2A). All females, regardless of hormone treatment, were equally protected against the 
ma2009dv H1N1 (Fig. 3.2B). Hemagglutinin stalk-specific antibodies recognize the conserved 
stalk region of the HA protein of IAVs and contribute to cross protection against diverse IAVs 
(178, 181). To assess whether titers of broadly neutralizing antibodies against the stalk of H1 may 
contribute to the similar level of protection against the ma2009dv observed in both placebo- and 
hormone-treated females following challenge, we measured stalk-specific antibody responses in 
serum at several time-points following the primary ma2009 H1N1 virus infection. Stalk antibody 
titers increased over time, peaking at 28 dpi in all female mice, and did not differ between 
placebo-treated and either P4- or LNG-treated females (Fig. 3.2C).  
To assess whether the P4-based treatments affected antibodies against the primary virus 
following the ma2009dv challenge, we measured serum anti-ma2009 neutralizing antibody and 
IgG titers pre- and post-challenge with ma2009dv. Following challenge with a drift variant virus, 
antibody responses to the primary virus were boosted at 21 days post-challenge in all treatment 
groups (Fig. 3.2D and E, P<0.05). Among all treatment groups, despite minimal pre-existing 
serum neutralizing antibody and IgG titers to the drift variant, following challenge with 
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maH1N1dv, serum neutralizing antibodies to the drift variant were detectable as early as two days 
post challenge and were associated with complete clearance of the virus from the lungs (Fig. 3.2F 
and data not shown). Serum anti-IAV IgG antibody responses against the ma2009dv also 
increased as early as two days post-challenge, but were lower in the placebo-treated as compared 
to P4- or LNG-treated females at 21 days post-challenge (Fig. 2G; P<0.05). Taken together, these 
data suggest that P4-based treatments did not alter broadly neutralizing stalk antibody responses 
or protection against a drift variant of H1N1, but increased total IgG antibody responses 
following challenge with ma2009dv. 
Progestins reduce protection against a heterologous IAV challenge while increasing 
antibody titers to the challenge virus 
 Treatment with either P4 or LNG did not affect the outcome of challenge with a 
homologous group 1 drift variant (Fig. 3.2B), but during influenza seasons both H1N1 and H3N2 
subtypes circulate. H1 and H3 IAVs are antigenically distinct, belonging to group 1 and group 2 
HA phylogenetic groups, respectively (322). To analyze the effects of progestins on a 
heterologous IAV challenge with a HA group 2 IAV, female mice were treated with either P4, 
LNG, or placebo, infected with ma2009 H1N1 virus, and challenged six weeks later with a 
maH3N2 virus, HK68, at a dose that is uniformly lethal in naïve animals (Fig. 3.3A). In contrast 
to primary IAV infection, placebo-treated females were protected against lethal maH3N2 virus 
challenge with 87% (13/15) of placebo-treated females surviving the challenge as compared to 
53% (8/15) of P4- and 43% (6/14) of LNG-treated females surviving infection (Fig. 3.3B; 
P<0.05). In the mice that survived the challenge, however, progestin treatment promoted faster 
recovery as compared to placebo treatment (Fig.3.3C; P<0.05), which is consistent with the 
effects during a primary infection (Fig. 3.1A and B). Treatment with either P4 or LNG did not 
alter H3N2 titers or clearance in the lungs (Fig. 3.3D).  
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To determine whether humoral immune responses during the heterosubtypic challenge 
were affected by progestins in the mice that survived the challenge, neutralizing and total IgG 
antibody responses against the primary ma2009 IAV and the secondary and heterologous HK68 
IAV were measured both prior to and after challenge. In contrast to the ma2009dv challenge (Fig. 
3.2D), when females were challenged with a heterosubtypic maH3N2 the titers of neutralizing 
antibody against the primary H1N1 IAV (i.e., ma2009) were not altered (Fig. 3.3E). Pre-existing 
serum neutralizing antibodies to HK68 were not detected in the serum prior to the challenge in 
any of the treatment groups (Fig. 3.3F), but titers against HK68 were significantly greater in P4- 
and LNG-treated females compared with placebo-treated females at 14 and 21 days post-
challenge (Fig. 3.3F; P < 0.05). Similarly, serum anti-HK68 IgG antibody titers were not detected 
prior to challenge, but were significantly greater at 21 days post-challenge in both P4- and LNG-
treated mice than in placebo-treated females (Fig. 3.3G; P<0.05). Although treatment with 
progestins reduced neutralizing antibody responses to primary IAV infection, these hormones 
significantly increased neutralizing antibody responses against a sequential infection with an 
antigenically unrelated IAV. Taken together, these data illustrate that in the context of a 
heterologous challenge, progestins increase antibody responses to sequential influenza A virus 
infection, without having an effect on antibodies against the primary virus, which may be 
beneficial for vaccine responses.  
Progestins increase pulmonary immunopathology following challenge with a heterologous 
IAV 
Because titers of HK68 were not different between placebo and progestin treated females 
(Fig. 3.3D), we sought to identify other possible mechanisms of differential mortality between the 
placebo- and progestin-treated females following a heterologous challenge. We analyzed 
pulmonary immunopathology in female mice that were treated with either P4, LNG, or placebo, 
infected with ma2009 H1N1 virus, and challenged six weeks later with a maH3N2 virus. Lungs 
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were inflated and fixed at 6 and 8 days post-challenge to encompass the average day of death for 
females in each of the progestin treatment groups (average day of death for P4: 7.8±0.7, and 
LNG: 6.6±0.2). No differences in overall inflammation scores were observed at day 6 post H3N2 
challenge across the treatment groups, but by day 8 post-challenge, females treated with either P4 
or LNG had greater inflammation, as characterized by increased alveolitis, necrosis, and edema as 
compared to placebo-treated females (Fig. 3.4A-C: P<0.05). Taken together, these data indicate 
that the increased mortality following a heterologous H3N2 challenge in progestin-treated 
females may be caused by excessive immunopathology in the lungs at the time of death. 
Progestins reduce memory CD8+ T cell responses against a heterologous IAV challenge  
Although antibody responses to the primary ma2009 H1N1 infection were significantly 
lower in P4- and LNG-treated females compared with placebo-treated females, antibody-
mediated immunity is not the primary mechanism of cross-protection against different groups of 
IAVs which possess distinct surface antigens, but share common core proteins that could be 
recognized by T cells. Populations of memory T cells mediate cross-protection against different 
groups of IAVs (180, 203-205) and were analyzed at several time points prior to and after 
challenge with the H3N2 IAV to determine if suppressed memory T cell numbers and activity in 
progestin-treated females may underlie the increased susceptibility to heterosubtypic infection. 
Treatment with either P4 or LNG did not alter numbers of total virus-specific CD4+ T cell, Th2 
cell, or Th17 cell subsets in the lungs but reduced numbers of Th1 cells after challenge (Table 
3.1). Frequencies of total CD8+ T cells and naïve CD8+ T cells also were not significantly 
different between placebo-, P4-, and LNG-treated mice prior to or after heterosubtypic IAV 
challenge (Table 3.1).  
Following challenge with a heterosubtypic maH3N2, the frequency of most virus-specific 
CD8+ T cell populations in the lungs increased over time, regardless of hormone treatment (Fig. 
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3.5A-D). Treatment of females with either P4 or LNG, significantly reduced the total number of 
ma2009-specific CD8+ T cells producing IFN-g, TNF-a, or both cytokines, as compared to 
placebo treatment at 6 days post-challenge (Fig. 3.5A-C; P<0.05). Tetramer-specific CD8+ T 
cells, that recognized either the ma2009- (i.e., primary IAV) or HK68- (i.e., secondary IAV) 
specific immunodominant NP peptides, also were lower at 6 days post-challenge in females 
treated with either P4 or LNG as compared to placebo (Fig. 3.5D; P<0.05).   
Total numbers of CD8+ memory (CD44+) T cells, following ex vivo stimulation with a 
peptide from ma2009, were also decreased 6 days following heterosubtypic IAV challenge in the 
females treated with either P4 or LNG as compared to placebo (Fig. 3.6A). This included both 
CD8+ tissue resident memory (TRM; CD8+CD44+CD69+CD103+), and CD8+ T central memory 
(TCM; CD8+CD44+CD62L+) cells (Fig. 3.6B-D; P<0.05). The total number of virus-specific 
memory CD8+ T cells producing IFN-g with or without TNF-a at days 2 and 6 post-challenge, 
and TNF-a producing memory CD8+ T cells at day 6 post-challenge were also significantly 
decreased in progestin-treated females as compared to females treated with placebo (Fig. 3.6E-G; 
P<0.05). Similarly, when memory CD8+ T cells were stimulated ex vivo with a HK68 peptide, 
the numbers of TNF-a+ producing CD8+ T cells, IFN-g+TNF-a+ producing CD8+ T cells, 
memory CD8+ T cells, CD8+ TRM cells, and CD8+ TCM cells were lower in the lungs of P4- 
and LNG-treated females than placebo-treated females at 2, 6, or both days post-challenge (Table 
3.2; P<0.05). Taken together, these data illustrate that IAV-specific memory CD8+ T cell 
numbers and activity, but not total CD8+ or CD4+ T cell numbers, were significantly reduced by 
progestin treatment during the heterosubtypic challenge.    
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Discussion 
A significant majority of women in the United States are exposed to some form of 
progestin in either hormone contraceptives or hormone-replacement therapy (20). Concurrently, 
women (and men) are exposed to novel strains of IAVs approximately every 5-10 years over the 
life course (318). The impact of progestins on the outcome and responses to infectious diseases at 
mucosal sites outside of the reproductive tract are rarely considered. In the present study, we 
show that while both P4 and LNG improved the outcome of IAV in immunologically naïve 
female mice, these hormones significantly reduced memory CD8+ T cell responses and thereby 
increased susceptibility to heterosubtypic challenge with novel strains of IAV. Surprisingly, and 
possibly beneficial for vaccine responses, both P4 and LNG improved antibody responses to 
subsequent IAV challenges. 
Following H1N1 infection and subsequent challenge with an H1N1 drift variant,  
placebo-, P4-, and LNG-treated females were equally protected, despite low pre-existing antibody 
responses to the ma2009dv, and reduced antibody responses to the primary H1N1 infection in 
progestin-treated females. The K166Q mutation is located in the globular head region of the HA, 
with the stalk regions of both the ma2009 H1N1 and the ma2009dv H1N1 being conserved (145). 
To address whether the protection following a drift variant virus challenge was due to antibody 
responses to the stalk region of the HA, we measured broadly neutralizing antibody responses to 
the conserved stalk region of the H1 HA using a chimeric HA containing an exotic H6 head and 
the stalk from the ma2009 H1N1 HA. Broadly neutralizing antibodies target epitopes within the 
HA stem region that are conserved within each phylogenetic HA group. In our study, broadly 
neutralizing stalk antibody responses were not affected by hormone treatment, which may explain 
why there was equal protection against another group 1 virus and complete clearance of the virus 
by two days post-challenge (178, 323). Additionally, the neutralizing antibody response to the 
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drift variant was boosted as early as two days post-challenge with the drift variant virus and may 
explain why these females were fully protected.  
Following H1N1 infection and subsequent challenge with a heterologous H3N2 strain of 
IAV, females treated with either P4 or LNG suffered greater mortality between 6 and 8 days post-
challenge. The increased susceptibility to the secondary heterologous IAV challenge was not 
caused by effects of either P4 or LNG on virus replication or clearance, but was associated with 
increased pulmonary immunopathology, including edema, alveolitis and necrosis, and impaired 
memory CD8+ T cell responses. Memory CD8 T cells are indispensable in the control of 
heterosubtypic IAV infection, and TRM cells, in particular, are the primary mediator of 
protection against secondary IAV challenge. Studies in mice show that if the entry of any non-
resident, circulating, memory T cells to the lungs is blocked, then the presence of tissue-
embedded TRM alone is sufficient to induce heterosubtypic immunity (208). In the current study, 
reduced virus-specific memory CD8+ T cell and CD8+ TRM cell activity were associated with an 
inability to survive heterosubtypic IAV challenge in P4 or LNG treated mice. Although the total 
numbers of pulmonary CD4+ or CD8+ T following H3N2 challenged females were not affected 
by progestins, the expansion of virus-specific CD8+ T cells that recognize both H1N1 and H3N2 
IAVs was restricted in progestin- compared to placebo-treated females. Furthermore, expansion 
of memory CD8+ T cell subsets occurred following stimulation ex vivo with either the H1N1 or 
H3N2 NP immunodominant peptide, which despite a three amino acid difference, is conserved 
across group 1 and group 2 viruses and elicit similar memory CD8+ T cell responses.  
The ability of CD8+ T  cells to rapidly expand and produce anti-viral cytokines, 
including TNF-a and IFN-g which can have synergistic effects, is crucial for both the clearance 
of the virus and the resolution of inflammation (324, 325). Mice with IFN-g deficient CD8+ T 
cells or complete TNF-a knock out mice have extensive inflammation and lung pathology with 
impairment of lung function following IAV infection, demonstrating the importance of these 
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cytokines not only in the clearance of the virus but also in resolution of infection-induced lung 
pathology (264, 326). The production of TNF-a and IFN-g by effector and memory CD8+ T cells 
in response to heterosubtypic IAV challenge was significantly impaired in females treated with 
either P4 or LNG. Consequently, both P4 and LNG treated females had increased pulmonary 
inflammation and lung pathology immediately following heterosubtypic IAV challenge. 
Progestins may prevent the production of IFN-g and TNF-a by IAV-specific CD8+ T cells by 
inhibiting signaling pathways in these cells. When bound to the progesterone receptor, progestins 
can directly interfere with both the NF-kB and MAPK pathways, which control the transcription 
of TNF-a and IFN-g (38, 43, 327, 328), suggesting a potential mechanism for the progestin-
mediated reduction of IFN-g and TNF-a within IAV-specific CD8+ T cells. 
 The impact of progestins on sequential exposure and memory responses to viral infection 
have only been evaluated in a few vaccine studies, mostly in the context of herpes simplex virus 
(HSV) infection. Following HSV-2 vaccination, progestin treatment decreases protection against 
a challenge, reduces virus-specific IgG and IgA antibody levels, and increases virus shedding (96, 
113). Several studies illustrate that progestins inhibit antibody production (60, 61), but most 
studies only consider this effect after an exposure to antigen in immunologically naïve animals. 
Consistent with these findings, in the current study, progestins significantly reduced titers of 
neutralizing and virus-specific IgG and IgA both in the serum and BAL in naïve females infected 
with IAV. A secondary virus infection with a drift variant virus resulted in a boost in titers to the 
primary virus in all treatment groups. However, both neutralizing and total IgG antibodies against 
the secondary challenge virus were significantly higher in P4 and LNG-treated females compared 
with placebo-treated females. Following secondary challenge with a drift variant of H1N1, 
progestin treatment reduced antibody responses to a primary IAV infection and increased 
antibody responses to a secondary IAV challenge as compared with placebo treatment, which 
may be beneficial in the context of vaccination.  
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The current usage of hormonal contraceptives is on the rise, with over 100 million 
women worldwide taking some form of progestin-based hormonal contraceptives. These 
hormone-based contraceptives are listed by the World Health Organization (WHO) as an essential 
medication because of their role in preventing excessive pregnancies and maternal morbidity. 
Additionally, in light of concerns about infectious diseases that can be transmitted from mother to 
fetus (e.g., Zika virus), the WHO, the Center for Disease Control in the United States, and other 
national health agencies recommend the use of hormonal contraceptives to prevent pregnancies 
and transmission of infections to the fetus. In this study, we demonstrate that the exposure to 
progestins in ovary-intact female mice, has beneficial effects on primary infection with IAV, but 
detrimental effects on the generation and activation of memory CD8 T cell responses and 
outcome of secondary infection. The impact of these responses in humans should be considered 
in human surveillance studies as well as vaccine trials to determine if contraceptives alter the 
outcome of IAV infection and responses to vaccination in women.  
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Materials and Methods 
Animals 
Adult (7-9 weeks old) female C57BL/6 mice were purchased from Charles River Laboratories 
(Frederick, MD) and housed up to 5 per microisolator cages under standard BSL-2 housing 
condition with food and water ad libitum. All animal procedures were approved by the Johns 
Hopkins University Animal Care and Use Committee under animal protocol M015H236. At 8-12 
weeks of age, mice were anesthetized with an intramuscular injection of ketamine (80 mg/kg) and 
xylazine (8 mg/kg) cocktail and hormones were administered in the form of a subcutaneous 
dorsal implant: 1) 15 mg progesterone (P4) 60-day release pellets (Innovative Research of 
America); 2) 5 mm levonorgestrel (LNG; Sigma) in a silastic capsule (0.040 i.d., 0.085 o.d.); or 
3) placebo as an empty silastic capsule. The capsules were equilibrated in sterile physiological 
saline at 37oC overnight prior to implantation. The doses of P4 and LNG increase P4 
concentrations, uterine horn mass, or both to within the physiological range of young 
nonpregnant female mice (131, 300, 301). 
Virus Infection, Quantification and Purification 
Mouse-adapted influenza A viruses, A/California/04/09 (ma2009;H1N1) generated by Dr. 
Andrew Pekosz from a published sequence (251) A/California/04/09 drift variant (ma2009dv; 
H1N1) containing the K166Q mutation of the HA sequence generated by reverse genetics. Viral 
RNA was extracted (QIAamp Viral RNA, Qiagen) from existing ma2009 IAV and transcribed 
into cDNA (SuperScript III, Invitrogen). HA specific cDNA was PCR amplified and purified on a 
1% agarose gel. Purified HA cDNA was digested and cloned into the pHH21 plasmid vector 
(329).  The K166Q HA mutation (145) was introduced by site directed mutagenesis (QuikChange 
Lightning Site-Directed Mutagenesis Kit, Agilent Technologies). Viruses encoding the K166Q 
HA mutation were generated entirely from cDNA using the 12 plasmid rescue system (329, 330). 
The HA sequence of the rescued virus was confirmed by sequencing the coding region of the HA 
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gene. Viral stocks were generated by infecting MDCK cells at a multiplicity of infection of 0.01 
and the infected cell supernatant was collected at 72 hours post-infection. A/Hong Kong/2/68 
(HK68; H3N2) was given to us courtesy of Innocent N. Mbawuike. All three viruses were used in 
these studies and infectious virus titers were determined using the 50% tissue culture infectious 
dose (TCID50) assay. For infections, mice were anesthetized with a ketamine (80 mg/kg) and 
xylazine (8 mg/kg) cocktail and inoculated intranasally with 30 µl of a low dose of ma2009 virus 
(0.04 50% mouse lethal dose [MLD50]) or mock-infected with DMEM alone. For challenge 
experiments, animals were inoculated with 30 µl of a lethal dose of HK68 (162 MLD50 in 30 µl of 
DMEM) or ma2009drift variant (32 MLD50) 6 weeks following the initial infection. 
 For virus quantification, a TCID50 assay was used in which, log10 dilutions of lung homogenates 
were plated onto a monolayer of Madin-Darby canine kidney (MDCK) cells in replicates of 6 for 
6 days at 32oC. Cells were stained with naphthol blue black (Sigma Aldrich) and scored for 
cytopathic effects. The TCID50 titer was calculated according to the Reed-Muench method. For 
virus purification, viruses were grown in MDCK cells at 37oC for 4 days and pelleted by 
centrifugation on a 20% sucrose gradient in a Beckman SW28TI rotor at 26,000rpm for 1h at 4oC. 
The virus pellet was resuspended in 1X PBS, protein was quantified by a BCA assay (Pierce) and 
aliquots were stored at -80oC. 
Morbidity and Mortality Studies 
Clinical scores as well as body mass, rectal temperature and survival were recorded daily over the 
course of the study. Clinical disease scores for IAV-infected mice were based on four parameters, 
with one point given for each of the following: dyspnea, piloerection, hunched posture and absence 
of an escape response (131). 
Serum and Bronchoalveolar lavage Sample Collection 
Serum and bronchoalveolar lavage (BAL) were collected at relevant time-points to measure 
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antibody titers and neutralizing antibodies. Mice were bled from the cheek for survival 
experiments or from the retro-orbital sinus for terminal procedures. Serum was heat-inactivated at 
56oC for 30min and stored at -80oC. For BAL collection, mice were euthanized by cervical 
dislocation and the lungs were lavaged twice with 0.5ml of a 0.9% saline solution. BAL fluid was 
centrifuged at 500g for 10 minutes to remove cells and debris and the supernatant was collected, 
heat inactivated at 56oC for 30min and stored at -80oC.  
Histopathology and Immunohistochemistry 
Lungs were inflated at constant pressure, fixed in Z-fix (Anatech) for at least 48h, embedded in 
paraffin, cut into 5µm sections, and mounted on glass slides. Tissue sections were stained with 
hematoxylin and eosin (H&E) and used to evaluate lung inflammation. Histopathological scoring 
was performed by a single blinded veterinary pathologist on a scale from 0-3 (0, no inflammation; 
1, mild inflammation; 2, moderate inflammation; and 3, severe inflammation) for the following 
parameters: bronchiolitis, alveolitis, vasculitis, perivasculitis, necrosis, consolidation, and edema 
(131). The percentage of lesioned areas within each tissue section was also evaluated. Images 
were taken using a Nikon Eclipse E800.  
Antibody Neutralization 
Serially-diluted serum was mixed with 100TCID50 of virus (ma2009 or HK68) for 1h at room 
temperature and used to infect quadruplicates wells of confluent MDC cells for 24h at 37°C. 
After 16-18h of incubation, the inoculum was removed and the cells washed with 1X PBS (with 
calcium and magnesium) and fresh media was added. The cells were incubated for 6 days at 32oC 
and then fixed with 4% formaldehyde and stained with napthtol blue black for 6h. The titer was 
calculated as the highest serum dilution that eliminated virus cytopathic effects in 2 out of 4 wells 
per dilution. 
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Anti-influenza ELISA 
ELISA plates (Microlon 96 well high binding plates; Greiner Bio-One) were coated with 100ng 
of purified virus overnight at 4oC in carbonate buffer (pH=9.6). For IgG ELISAs, plates were 
washed 3 times with PBST (1X PBS + 0.1% Tween-20 (Sigma)) and blocked for at least 1h at 
37oC with 10% dry milk powder in 1X PBS. Plates were washed 3 times prior to the addition of 
serially diluted serum to the plates for 1h at 37oC at a starting dilutions of 1:1000. Anti-mouse 
horseradish peroxidase (HRP) conjugated secondary IgG (1:5000; Thermo) was added and plates 
were incubated for 1 h at 37oC. The plates were washed 3 times with PBST and reactions were 
developed with 3,3’,5,5’ tetramethylbenzidine (TMB; BD Biosciences) and stopped using 1N 
HCl. Plates were read at 450 nm absorbance on a plate reader. For IgA ELISAs, plates were 
washed 3 times with TBST (1X TBS + 0.1% Tween) and blocked for at least 1h at 37oC with 
10% dry milk powder in 1X TBS. Plates were washed 3 times prior to the addition of serially 
diluted BAL to the plates for 1h at 37oC at a starting dilutions of 1:1. Anti-mouse alkaline 
phosphatase (AP) secondary IgA (1:2000; Southern Biotech) was added and plates were 
incubated for 1 h at 37oC. The plates were washed 3 times with TBST and reactions were 
developed with p-nitrophenyl phosphate substrate (PNPP; Thermo) and stopped using 2N NaOH. 
Plates were read at 405nm absorbance on a plate reader. To determine the antibody titer, a cutoff 
value was determined by multiplying the average OD values of the negative controls at each 
dilution by 3. The titer for the sample was calculated as the highest serum dilution with an OD 
value above the cutoff.  
Stalk antibody ELISA 
Flat bottom Immuno 4HBX 96-well plates (Thermo) were coated overnight at 4 oC with 100ng of 
recombinant HA using the chimeric cH6/1 protein (with the A/mallard/Sweden/81/02 H6 head 
and a A/Cal/04/09 stalk domain generated as described previously (331) in carbonate buffer 
(pH=9.4). Plates were washed 3 times with PBST and blocked for at least 1h at room temperature 
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with 3% goat serum (Gibco) and 0.5% milk powder in PBST. Plates were washed 3 times prior to 
the addition of serially diluted (2-fold dilution) samples added a starting dilution of 1:100. 
Samples were incubated for 2h at room temperature, washed and anti-mouse IgG-peroxidase 
(HRP) conjugated secondary antibody was added (1:3000; A9044; Sigma) and plates were 
incubated for 1h at room temperature. The plates were washed 3 times and developed with o-
phenylenediamine dihydrochloride (OPD; Sigma) and stopped after 10min using 3M HCl. Plates 
were read at 490nm on a plate reader. To determine the antibody titer, a cutoff value was 
determined by calculating the average OD values of the negative controls for each plate and 
adding the standard deviation. The titer for the sample was calculated as the highest serum 
dilution with an OD value above the cutoff. 
Flow Cytometry Analysis of T cells 
Lungs were excised and single-cell suspensions were generated following red blood cell lysis. 
Total viable cells were determined using a hemocytometer and trypan blue (Invitrogen) exclusion 
and resuspended at 1x106 cells/ml in RPMI 1640 (Cellgro) supplemented with 10% FBS (Fisher 
Scientific) and 1% penicillin/streptomycin. For IAV-specific T cells enumeration, cells were 
cultured for 5h with IAV peptide antigen (CD8:NP366-374, or CD4: HA211-255, NP311-325, 
respectively) (ProImmune), PMA (Sigma) and Ionomycin (Sigma) or media alone (unstimulated) 
in media containing Brefeldin A (GolgiPlugA) The viability of cells was determined by fixable 
Live/Dead aqua viability dye (Invitrogen) and Fc receptors were blocked using anti-CD16/32A. 
The T cell populations were stained with the following antibodies: FITC conjugated anti-CD3 
(17A2)A, AF700 conjugated anti-CD4 (RM4-5)A, PerCP-Cy5.5 conjugated anti-CD8 (53-6.7)B, 
APC conjugated anti-CD44 (IM7)A, eVolve 605 conjugated anti-CD62L (MEL-14)B, eFluor 450 
conjugated anti-CD69 (H1.2F3)B, PE conjugated anti-CD103 (M290)A, PE conjugated DbNP366-374 
tetramer for ma2009 (ASNENVETM, NIH Tetramer Core Facility) and BV421 conjugated 
DbNP366-374 tetramer for HK68 (ASNENMDAM, NIH Tetramer Core Facility). Intracellular 
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staining with PeCy7 conjugated anti-IFN-g (XMG1.2)A, FITC conjugated anti-TNF-a (MP6-
XT22)A, BV412 conjugated anti-IL4 (11B11)A, APC conjugated IL-17 (eBio17B7)B, was 
performed following permeabilization and fixation with Cytofix/Cytoperm and Perm/Wash 
bufferA. Data were acquired using a FACS Fortessa (FACS DIVA Software) and analyzed using 
FlowJo v.10 (Tree Star, Inc.). Total cell counts were determined by multiplying each live cell 
population percentage by the total live cell counts acquired prior to staining by trypan blue 
exclusion counts on a hemocytometer. All reagents were purchased from BD BiosciencesA or 
eBioscienceB unless stated otherwise. 
Statistical Analyses 
Morbidity and clinical data were analyzed with a MANOVA followed by planned comparisons. 
Antibody titers, virus titers, and histopathological data were analyzed using two-way ANOVAs or 
t-tests and significant interactions were further analyzed using the Tukey method for pairwise 
multiple comparisons. Survival was analyzed using a Kaplan Meyer survival curve followed by a 
log-rank test. Mean differences were considered statistically significant if P<0.05.   
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Figure and table legends 
Figure 3.1: Progesterone (P4) and levonorgestrel (LNG) treatment reduced morbidity and 
antibody production during primary H1N1 IAV infection. Adult female mice were treated 
with placebo, progesterone (P4), or levonorgestrel (LNG) and inoculated intranasally with a low 
dose of ma2009 H1N1 virus. Mice were monitored daily for changes in body mass (A) and 
clinical disease (B) for 21 days post-inoculation (dpi). Serum was collected at 14, 21, 28, and 35 
dpi and anti-ma2009 IgG titers were measured by ELISA (C) and ma2009 neutralizing antibody 
titers were analyzed by neutralization assay (D) (n=30/treatment/time-point). Bronchoalveolar 
lavage (BAL) fluid was collected at 14, 21, and 28dpi and analyzed for anti-ma2009 IgA titers 
(E) and neutralizing antibody titers (F) (n=8-10/treatment/time-point). The stippled line 
represents the antibody levels for naïve animals. Data represent means ±SEM from three 
independent replications and significant differences between P4 and placebo are represented by 
asterisks (*), and between LNG and placebo by a pound sign (#). 
Figure 3.2: Neither progesterone (P4) nor levonorgestrel (LNG) treatment altered 
protection following challenge with a ma2009 H1N1 drift variant in females. Adult female 
mice were treated with placebo, progesterone (P4), or levonorgestrel (LNG) and inoculated 
intranasally with a low dose of ma2009 H1N1 virus. Six weeks later, mice were challenged 
intranasally with a high dose of a ma2009 drift variant (K166Q) H1N1 virus and euthanized at the 
indicated time-points (A). Mice (n=10/treatment) were monitored for changes in body mass (B) 
for 21 days post-challenge. Broadly neutralizing stalk antibodies were measured in serum 
collected at 14, 21, 28, and 35 days post primary infection using a stalk antibody ELISA with an 
exotic HA head and conserved ma2009 H1N1 stalk (cH6/1) (C; n=25-30/treatment/time-point). 
Neutralizing antibody responses (D) and IgG titers (E) against the primary ma2009 H1N1 virus 
and were measured in serum collected prior to (pre-challenge; 21 days post primary infection) 
and 21 days post-challenge (n=10/treatment/time-point). Neutralizing antibody responses (F) and 
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IgG titers (G) against ma2009 drift variant (dv) H1N1 virus were measured in serum collected 
prior to (pre-challenge; 21 days post primary infection) and 2, 6, 14, or 21 days post-challenge 
(n=10/treatment/time-point). The stippled line represents the antibody levels for naïve animals. 
Data represent means ±SEM from two independent replications and significant differences 
between P4-treated and placebo-treated females are represented by asterisks (*), between LNG-
treated and placebo-treated females by a pound sign (#), and between pre- and post-challenge 
within a treatment group by a plus sign (+). 
Figure 3.3: Progesterone (P4) and levonorgestrel (LNG) treatments reduced survival, but 
increased antibody titers following challenge with a heterosubtypic H3N2 influenza A virus. 
Adult female mice were treated with placebo, P4, or LNG and inoculated intranasally with a low 
dose of ma2009 H1N1 virus. Six weeks later, ma2009 H1N1 infected mice were challenged 
intranasally with a high dose of HK68 H3N2 virus and euthanized at the indicated days post-
challenge (A). These female mice (n=15/treatment) were monitored for changes in mortality (B) 
and body mass (C) for 21 days post-challenge. Infectious virus titers in the lungs were measured 
at 2, 4, 6, and 8 days post-challenge (D; n=5-8/treatment/day). Neutralizing antibody titers (E) 
against the primary ma2009 H1N1 virus were measured in serum collected prior to (pre-
challenge; 21 days post primary infection) and 21 days post-challenge (n=10/treatment/time-
point). Neutralizing antibody responses (F) and IgG titers (G) against the HK68 H3N2 virus were 
measured in serum collected prior to (pre-challenge; 21 days post primary infection) and 6, 14, or 
21 days post-challenge (n=10/treatment/time-point). The stippled line represents the antibody 
levels for naïve animals. Data represent means ±SEM from two independent replications and 
significant differences between P4 and placebo are represented by asterisks (*), and between 
LNG and placebo by a pound sign (#). 
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Figure 3.4: Progesterone (P4) and levonorgestrel (LNG) treatments increased pulmonary 
immunopathology following challenge with a heterosubtypic H3N2 influenza A virus. Adult 
female mice were treated with placebo, progesterone (P4), or levonorgestrel (LNG) and 
inoculated intranasally with a low dose of ma2009 H1N1 virus. Six weeks later, mice were 
challenged intranasally with a high dose of HK68 H3N2 virus. H&E stained lung sections 
collected at 6 and 8 days post-challenge were scored for inflammation as a cumulative score of 
perivasculitis, bronchiolitis, alveolitis, edema, and necrosis (A). Separate scores at 8 days post-
challenge (dpc) for perivasculitis, bronchiolitis, alveolitis, edema, and necrosis are shown (B). 
Representative images of overall inflammation (2X magnification) and focused areas (10X 
magnification) with cellular infiltration and edema are shown (C) (n=5/treatment/day). Data 
represent means ±SEM from two independent replications and significant differences between P4 
and placebo are represented by asterisks (*), and between LNG and placebo by a pound sign (#). 
Figure 3.5: Treatment with either progesterone (P4) or levonorgestrel (LGN) reduced virus-
specific CD8+ T cell in the lungs of female mice challenged with a heterosubtypic H3N2 
influenza A virus. Adult female mice were treated with placebo, progesterone (P4), or 
levonorgestrel (LNG) and inoculated intranasally with a low dose of ma2009 H1N1 virus. Six 
weeks later, mice were challenged intranasally with a high dose of HK68 H3N2 virus. Lung 
single cell suspensions were harvested for flow cytometry analysis at 42 days post primary 
infection (i.e., prior to challenge; labeled day 0 post-challenge), and at days 2 and 6 days post-
challenge, and stimulated ex vivo with a ma2009-specific antigen in presence of BFA. Total 
numbers of live CD8+ T cells expressing IFN-g (A), TNF-a  (B), IFN-g and TNF-a (C), total 
numbers of live tetramer specific CD8+ T cells (D) were quantified. Data represent means ±SEM 
from two independent replications (n=8/treatment/day) and significant differences between P4 
and placebo are represented by asterisks (*), and between LNG and placebo by a pound sign (#). 
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Figure 3.6: Treatment with progesterone (P4) or levonorgestrel (LGN) reduced virus-
specific memory CD8+ T cell responses in the lungs of female mice challenged with a 
heterosubtypic H3N2 influenza A virus. Adult female mice were treated with placebo, 
progesterone (P4), or levonorgestrel (LNG) and inoculated intranasally with a low dose of 
ma2009 H1N1 virus. Six weeks later, mice were challenged intranasally with a high dose of 
HK68 H3N2 virus. Lung single cell suspensions were harvested for flow cytometry analysis at 42 
days post-primary infection (i.e., prior to challenge; labeled day 0 post-challenge), and at 2 and 6 
days post-challenge, and stimulated ex vivo with a ma2009-specific NP antigen in presence of 
BFA. Cells were gated on lymphocytes (SSC vs FSC) and doublets (FSCH-H vs FSC-A) and 
dead cells (viability dye+) were excluded. CD8+ or CD4+ T cells were determined from the live 
cell gate. Memory T cell (CD44+CD62L-), T central memory (TCM; CD44+CD62L-) and naïve 
CD8+ T cells (CD44-CD62L+) were gated on the CD8+ T cell subset. Tissue resident memory 
(TCM) cells were gated based on their expression of CD103 and CD69 from the CD44+CD62L- 
memory T cell gate (A). Total numbers of live memory CD8+ T cells (B), tissue resident memory 
CD8+ T cells (TRM; C), central memory CD8+ T cells (TCM; D), and memory CD8+ T cells 
expressing IFN-g (E), TNF-a (F) or both (G) were quantified. Data represent means ±SEM from 
two independent replications (n=8/treatment/day) and significant differences between P4 and 
placebo are represented by asterisks (*), and between LNG and placebo by a pound sign (#). 
Table 3.1: Total numbers of virus-specific CD4+ and CD8+ T cell recognizing ma2009 in 
the lungs of female mice following challenge. Adult female mice were treated with placebo, 
progesterone (P4), or levonorgestrel (LNG) and inoculated intranasally with a low dose of 
ma2009 H1N1 virus. Six weeks later, mice were challenged intranasally with a high dose of 
HK68 H3N2 virus. Lung single cell suspensions were harvested for flow cytometry analysis at 42 
days post primary infection (i.e., prior to challenge; referred to as day 0 post-challenge), and at 
days 2 and 6 days post-challenge and stimulated ex vivo with ma2009-specific antigen in presence 
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of BFA. Total numbers of live T cells were analyzed. Data represent means ±SEM from two 
independent replications (n=8/treatment/day) and significant differences are between P4 and 
placebo represented by asterisks (*), and between LNG and placebo by a pound sign (#). 
Table 3.2: Total numbers of virus-specific CD8+ T cell recognizing HK68 in the lungs of 
female mice following challenge. Adult female mice were treated with placebo, progesterone 
(P4), or levonorgestrel (LNG) and inoculated intranasally with a low dose of ma2009 H1N1 
virus. Six weeks later, mice were challenged intranasally with a high dose of HK68 H3N2 virus. 
Lung single cell suspensions were harvested for flow cytometry analysis at 42 days post primary 
infection (i.e., prior to challenge; labeled as day 0 post-challenge), and at days 2 and 6 days post-
challenge and stimulated ex vivo with HK68-specific antigen in presence of BFA. Total numbers 
of live T cells were analyzed. Data were analyzed with two-way ANOVA followed by Tukey 
tests and represent means ±SEM from two independent replications (n=8/treatment/day) and 
significant differences are between P4 and placebo represented by asterisks (*), and between 
LNG and placebo by a pound sign (#). 
  













































































































































































Figure 3.2  
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Table 3.1 
  Days Post-Challenge 
Total cells Treatment 0 2 6 
CD4+ T cells Placebo 8230±662 6829±1480 32752±3067 
 P4 8093±1720 9511±1951 29904±3816 
 LNG 7018±857 7017±1424 27204±3200 
IFN-g+ CD4+ T cells Placebo 86.35±9.2 185.7±32.3 883±114 
 P4 93.04±21.1 244±35.1 551.6±101 * 
 LNG 83.63±12.2 159.8±35.3 454±81.3 # 
IL-4+ CD4+ T cells Placebo 19.72±5.6 8.71±4.0 22.84±6.1 
 P4 28.36±10.8 14.88±7.8 26.75±5.4 
 LNG 20.72±7.6 5.96±2.8 18.63±4.4 
IL-17+ CD4+ T cells Placebo 46.76±14.2 26.62±9.5 34.24±11.0 
 P4 67.85±24.5 33.64±7.7 29.27±11.3 
 LNG 42.76±24.2 41.68±11.3 31.31±12.3 
CD8+ T cells Placebo 8958±823 11275±2590 55003±13269 
 P4 9798±400 15512±5861 44293±7757 
 LNG 12192±2273 12215±1289 45214±9833 
Naïve CD8+ T cells Placebo 4413±608 3500±1271 5530±380 
 P4 4372±1272 2365±650 5633±814 
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Table 3.2  
  Days Post-Challenge 
Total  T cells Treatment 0 2 6 
IFN-g+ CD8+  Placebo 73.3±17.3 246.7±92.7 12183±4127 
 P4 52.5±11.6 352.9±124.9 6993±31.22 
 LNG 65.3±13.1 235.7±85.6 7204±125.6 
TNF-a+ CD8+  Placebo 209.4±78.6 1125±582 26323±8405 
 P4 171.0±42.0 207.1±25.74 10609±5160 * 
 LNG 120.2±39.6 1296±586.7 12849±5691 # 
IFN-g+TNF-a+ CD8+ Placebo 37.5±8.8 74.7±39.3 262.8±41.9 
 P4 28.9±4.6 25.39±4.5 107.0±23.6 * 
 LNG 21.7±3.8 53.56±43.4 66.09±12.2 # 
Memory CD8+ Placebo 3462±566.2 5395±1793 47865±5875 
 P4 2523±627.0 3439±765.4 26862±5207 * 
 LNG 3384±556.5 4548±1152 23661±4660 # 
TRM CD8+ Placebo 82.0±14.6 167.6±66.8 1843±449.3 
 P4 51.7±18.2 176.0±53.6 826.6±318.6 * 
 LNG 64.3±9.8 152.5±46.0 710.8±258.4 # 
TCM CD8+ Placebo 1765±401.3 842.0±297.0 12804±2494 
 P4 1261±277.9 617.0±206.1 8660±2075 * 
 LNG 1404±259.6 1174±121.8 5641±710.0 # 
IFN-g+ CD8+ Memory Placebo 21.0±7.1 365.1±164.7 444.3±96.3 
 P4 11.9±4.6 342.5±120.3 258.8±98.8 
 LNG 17.0±3.9 232.9±119.3 242.0±52.0 
TNF-a+ CD8 Memory Placebo 106.5±48.8 706.9±376.2 1071±209.1 
 P4 60.1±14.7 81.3±26.8 * 373.8±94.1 * 
 LNG 45.2±16.5 398.7±259.8 320.0±84.9 # 
IFN-g+ TNF-a+ CD8 
Memory Placebo 12.1±2.1 79.2±50.3 45.9±10.4 
 P4 7.7±1.1 11.15±3.8 * 20.96±8.2 
 LNG 7.7±2.9 28.2±16.8 # 16.5±5.3 
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The research within this dissertation illustrates the need for a better understanding of the 
role of sex steroid hormones in infectious diseases. More precisely, the findings of this 
dissertation demonstrate a novel mechanism for progesterone in the protection of IAV-infected 
mice by decreasing inflammation, promoting repair and altering memory and antibody responses. 
These findings may be applicable for other disease models and their implication in human clinical 
research remains to be further explored.  
Progesterone protects female mice from IAV infection 
Severe infections with IAV may lead to excessive inflammation and pulmonary damage 
that can cause severe disease and even death (153, 264, 265). In chapter 2, I made the unique 
observation that treatment of female mice with a host factor, the sex steroid hormone P4, can 
prevent immunopathology and decrease mortality following lethal IAV infection. This 
observation was expanded to female mice infected with a sub-lethal dose of IAV, and in addition 
to decreasing inflammation and immunopathology, P4 promotes repair and leads to faster 
recovery. This is consistent with the literature which demonstrates an anti-inflammatory and 
repair role of P4 in infectious disease and in autoimmune diseases such as multiple sclerosis (39, 
44, 64, 67, 95, 101).  As highlighted in the introductory chapter, the anti-inflammatory role of P4 
may be a disadvantage when a strong pro-inflammatory response is needed, however, in the 
context of IAV infection where there is a tendency of the host to induce excessive inflammation 
in response to the infection, treatment with P4 and regulation of the inflammation is beneficial.  
Progesterone promotes pulmonary repair following IAV infection 
Mice infected with IAV suffer from extensive lung tissue damage due to the cytokine 
storm initiated by the host immune response to clear the virus (264, 265). This pulmonary injury 
needs to be rapidly repaired following virus clearance, and inflammation dampened in order for 
the lungs to function optimally and for full recovery of the mice. Several mechanisms of 
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pulmonary repair following IAV infection have been elucidated and all concern host factors that 
come in place during the infection to promote proliferation of epithelial cell and pulmonary tissue 
remodeling. In mice treated with P4, four different repair mechanisms involving host proteins 
promote tissue remodeling following IAV infection: upregulation of TGF-b, increase in 
regulatory CD39+ Th17 cells, upregulation of IL-22 and increases in amphiregulin (AREG) 
production.  
TGF-b and repair 
TGF-b has a potent role in repair and homeostasis of injured tissues and is produced by a 
vast variety of cell types including epithelial cells and immune cells, each of which could 
potential respond to P4 and induce production of TGF-b during IAV infection. I hypothesize that 
P4 may exert its effects by acting synergistically on multiple cell types at once to produce TGF-b. 
This could be assessed by looking at the total numbers of PR+ cells producing TGF-b by flow 
cytometry in the lungs of IAV infected mice and comparing P4 treatment to placebo. Any cell 
types identified to produce TGF-b in response to P4 treatment during IAV infection could then be 
further investigated by using PR-floxed mice to knockout the PR from each of these cell types 
and measure any differences in lung pathology and pulmonary repair.   
The role of suppressive Th17 cells in repair 
Th17 cells are generally considered pro-inflammatory and exacerbate inflammatory 
diseases such as inflammatory bowel disease (IBD), collagen-induced arthritis and EAE (332, 
333). Recently, a population of Th17 cells has been shown to have a regulatory role similar to 
that of Tregs (306, 307). They are characterized by the expression of the ectonucleotidases CD39 
which allows the conversion of ATP to adenosine and dampens inflammation in lungs and other 
tissues (306, 334-338). The expression of CD39 on these cells is dependent on the presence of 
TGF-b and IL-6 which we also show to be increased following P4 treatment of IAV-infected 
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mice (131, 306). Regulatory CD39+ Th17 cells are increased following P4 treatment of IAV-
infected mice to decrease overall inflammation and induce the production of IL-22 to promote the 
repair of epithelial cells, but the precise role of these cells remains to be further explored. The 
manipulation of CD39+ Th17 cells poses technical difficulties as many other cell types also 
express CD39, including monocytes macrophages, DCs, and Tregs (334, 336, 339). Therefore, 
removing all cells expressing CD39 will not allow for a better understanding of the exact role of 
these regulatory Th17 cells. The best way to further characterize these cells would be in an in 
vitro culture system using naïve CD4+ T cells differentiated into Th17 cells in the presence of P4 
to assess their suppressive role in the presence of CD8+ OT-I T cells stimulated with the 
SINFELK peptide as compared to non-P4-treated cells, similarly to what was done by Chalmin et 
al. (306). Additionally, their precise role in repair could be further characterized by using 
differentiated CD39+ Th17 in a co-culture system with primary pulmonary epithelial cells 
infected with IAV, in the presence or absence of P4 and analyzing the role of the suppressive 
Th17 in dampening inflammation and promoting faster repair.  
Progesterone promotes repair through the production of amphiregulin 
Amphiregulin (AREG) is involved in pulmonary tissue remodeling and repair during 
many different aspects of lung pathology including lung injury, asthma, and infection (273, 279-
286). In IAV infection, AREG protects mice by decreasing hypothermia, reducing protein 
leakage and promoting faster recovery (131, 279, 280). In chapter 2, I identified a role for P4 on 
inducing AREG production and the requirement of this factor for P4-induced pulmonary repair in 
IAV-infected mice, using both administration of AREG in P4-depleted mice to restore protection 
and depletion of AREG in P4-treated mice to show a defect in repair and protection when AREG 
is lacking. I also show that epithelial cells are the main producers of AREG and, in vitro, are 
capable of promoting P4-induced repair following a mechanical injury. 
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A new definition for recovery following IAV infection 
All of these host factors lead to the proliferation of lung epithelial cells and help maintain 
the integrity of the epithelial barrier, allowing for a faster return to homeostatic conditions and 
improved pulmonary functions including gas exchange and airway elasticity. This research also 
highlights that despite complete clearance of the virus by 14dpi and return to homeostatic body 
mass and temperature by 21dpi, damage may persist in the lungs and hinder pulmonary lung 
function. Most IAV mouse studies use the return to baseline of either body mass or temperature 
as a measure of recovery, with studies even defining recovery at earlier stages (311, 340). These 
classical factors need to be reconsidered as this dissertation shows that despite a return to baseline 
for body mass and temperature, severe damage and inflammation may persist in the lungs and 
cause long-term defects in pulmonary function. This persistent pulmonary damage may also lead 
to increased opportunistic secondary bacterial infections which are a major concern following 
IAV infections (341-343). It would be interesting to test the role of secondary bacterial infections 
in our model of IAV infection in P4-treated mice. Despite the rapid repair of the damaged lungs, 
a dampening in immune responses promoted by P4 may hinder adequate responses to the 
bacterial challenge as observed in tuberculosis or chlamydia models of infection (94, 121, 130).  
Expanding the role of P4 on repair beyond IAV infections 
These repair factors also play a role in a variety of other types of lung injuries including 
infection with respiratory syncytial virus (RSV), acute lung injury and bacterial infections with 
the induction of similar pulmonary pathogenesis (274, 284, 344-346). The in vitro experiments 
from chapter 2 using mouse tracheal epithelial cells demonstrate that P4 can also promote the 
repair of mechanical injuries to the epithelium in the absence of a viral infection, which suggests 
that the protective role of P4 can be expanded beyond influenza infection and beyond viral 
infections all together. Studies to further understand the role of P4 in pulmonary repair are 
required and would involve testing P4 treatment in a non-pathogenic lung injury model such as 
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the bleomycin-induced lung injury model or using a model of pulmonary bacterial infection. I 
hypothesize that P4 would also promote the induction of similar host factors including AREG 
production to induce the proliferation and repair of the injured epithelium and foster a faster 
return to a healthy pulmonary environment. In terms of translating these findings into the clinic, 
administration of P4 is currently under phase 2 and phase 3 clinical trials for the treatment of 
traumatic brain injury and under review for clinical trial in the treatment of ischemic stroke in 
both men and women (29, 31, 32, 75, 347).   
The benefits of the use of P4 or a synthetic progestins in the treatment of IAV infection in 
humans, is that unlike antivirals, it may not be necessary to administer treatment at early stage of 
infections which are harder to capture due to the nature of the infection. If P4 could help in the 
treatment of IAV infection, due to its role during the recovery phase, its value may be in cases 
with severe ARDS complications. The role of P4 in dampening IAV-induced infection is also 
non-negligible and could help prevent the development of ARDS. This needs to be initially tested 
in mice by administering P4 at later time-points during IAV infection, such as 7 or 14 dpi and 
evaluating the effects of P4 during these later stages. Additionally, further understanding of the 
cells expressing PR and responding to P4 is also necessary.  
Characterizing the effects of P4 signaling on different cell types 
A large variety of cells including NK cells, macrophages, dendritic cells (DCs), T cells as 
well as non-immune cells, such as epithelial cells, endothelial cells, and neuronal cells express 
PRs (12, 13). In chapter 2, I have demonstrated that IAV-infected lungs of mice treated with P4 
have increased expression of PR, that tracheal epithelial cells express PR, and that epithelial cells 
are the main producers of AREG and may be doing so in response to P4 signaling. I hypothesize 
that epithelial cells may be the main cell type responding to P4 treatment to produce repair factors 
such as AREG and TGF-b but this remains to be further assessed. To do so, flow cytometry 
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analysis of the different cell types present in the lungs following IAV infection and P4 treatment 
is necessary to characterize their PR expression. Furthermore, to assess whether the presence of 
PRs on these cells has any functional relevance, it is necessary to narrow down which cells 
respond to P4 and are increased as compared to placebo-treatment. A way to evaluate this 
involves the use of PR-floxed mice and mice expressing Cre recombinase in different cell types. 
However, this approach involves a great number of different combinations of cre-inducible cells 
and corresponding mice and would prove very timely to investigate. A better approach perhaps 
would be with a bone marrow chimera model using irradiated PRKO mice and performing an 
adoptive transfer of bone marrow hematopoietic cells from wild type mice, treating these mice 
with P4 and infecting them with a sub-lethal dose of IAV. If the protective effects of P4 remain, 
this would indicate that the presence of PR on non-hematopoietic cells such as epithelial cells is 
not necessary for P4 to induce its protective effects. Conversely, irradiated wild-type mice with 
intact PR on non-hematopoietic cells can receive a bone marrow transfer from PRKO mice to 
replenish the hematopoietic cell population, be treated with P4 and infected with IAV. If the 
protective effects of P4 remain, this would indicate that the presence of PR on non-hematopoietic 
stem cell is necessary and that these cells respond to P4 and mediate the protective effects. My 
data shows that this might be the most likely scenario as epithelial cells are the main producers of 
AREG. 
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Figure 4.1: Summary of the effects of P4 on IAV pathogenesis. IAV infects airway epithelial 
cell which can produce pro-inflammatory cytokines and activate immune cells such as alveolar 
macrophages (green cells), DCs and neutrophils (in purple) that causes inflammation and along 
with CD8+ T cells (not depicted), lead to virus clearance. The presence of P4 leads to the 
production of IL-6 and TGF-b which can promote regulatory CD39+ Th17 cells differentiation 
and induce an anti-inflammatory milieu. Th7 cells can also produce IL-22, which, like TGF-b 
promote proliferation of epithelial cells and repair of the damaged epithelium. AREG is another 
factor that is induced by P4 signaling through the progesterone receptor (PR). AREG signals 
through the epidermal growth factor receptor (EGFR) to induce the proliferation of epithelial 
cells, which leads to repair of the damaged epithelium. 
Progestins alter antibody responses 
Female mice treated with either P4 or LNG experience lower titers of total anti-IAV IgG, 
IgA and virus neutralizing antibody titers in the serum and bronchoalveolar lavage (BAL) fluid 
following a primary IAV infection as compared to placebo-treated mice. These effects are even 
more pronounced in the BAL fluid, where levels of IgA and neutralizing antibodies are barely 
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detectable at 28dpi. This difference may be due to progestins hindering the ability of B cells to 
class-switch, or due to a difference in the numbers of antibody-secreting cells (ASCs). Very little 
is known on the role of progestins on B cells and this is an area that requires further investigation. 
To do so, total numbers of IgA+ or IgG+ B cells as well as virus-specific IgG or IgA ASCs could 
be evaluated by flow cytometry and ELISPOT assay respectively. This would indicate whether 
progestins have a direct effect on the numbers of B cells and their ability to produce either IgG or 
IgA. Furthermore, class-switching could also be evaluated by looking at the different subclasses 
of IgG, including IgG1 and IgG2c, and ratios of IgM to IgG to assess whether progestins could 
impact the ability of B cells to class-switch to isotypes which induce better protection from IAV 
(187-190). 
Progestins impair memory CD8+ T cell responses following IAV infection 
Following challenge with a heterosubtypic H3N2 virus, progestin-treated mice suffer 
from greater mortality compared to placebo-treated mice which could not be explained by 
differences in virus replication. Lung immunopathology in the progestin-treated mice is increased 
during the window in which the mice succumb to the challenge. These differences in the survival 
of progestin-treated mice correspond to a decrease in various populations of memory CD8+ T 
cells including cytokine-producing cells. Tissue-resident memory CD8+ T cells in particular, are 
decreased following either P4 or LNG treatment, and these cells are crucial in mediating 
protection against a heterosubtypic IAV challenge (206-208). Interestingly, similar studies show 
that control of infection in mice vaccinated and challenged with HSV-2 also require TRM (348). 
Progestins have been shown to decrease protection in HSV-2 challenge studies, however in these 
studies, TRM memory cells have not been measured (113, 118, 119). To date, no studies have 
evaluated the effects of progestins on the generation of memory CD8+ T cells and I hypothesize 
that progestin may not only affect total numbers of memory CD8+ T cells but also their 
phenotype. I hypothesize that less inflammation during the primary infection may both decrease 
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the amount of chemokines and recruitment of cells into the lungs which could then become 
resident memory cells along with a faster resolution of the infection which may decrease the 
availability of antigen and decrease antigen presentation and CD8+ T cell activation and 
differentiation. Additionally, the presence of progestins during the primary IAV infection may 
alter the interactions between naïve CD8+ T cells and antigen presenting cells. For example, 
progesterone decreases the expression of the co-stimulatory molecules CD80 and CD86 on DCs 
(33, 39) which may impact the generation of memory CD8+ T cells during a primary sub-lethal 
IAV infection. We observed an increase in IFN-g- and or TNF-a-producing memory T cells but 
have not evaluated their cytotoxic activity which can be done by looking at their production of 
perforin or granzyme B by flow cytometry. Because there is no difference in pulmonary virus 
titers or virus clearance between the placebo- and progestin-treated mice, I hypothesize that the 
cytolytic activity of these memory CD8+ T cells may not be decreased following progestin 
treatment. Rather the quality of the response may be decreased and lack specificity in the 
progestin-treated mice which leads to greater overall inflammation that we observe in the form of 
increased pulmonary immunopathology.  
Because of such differences in memory CD8+ T cell responses, it would be interesting to 
evaluate the longevity of these anti-influenza immune responses, as humans are thought to be re-
exposed to IAVs every 5-10 years (318). With time, cellular memory responses have a tendency 
to wane and this could lead to even greater susceptibility following sequential IAV challenge in 
progestin-treated mice. As such, it would be of interest to evaluate cellular and humoral response 
to an IAV challenge, not six weeks post primary infection, but several months later. Because 
TRM confer long-lasting immunity, I hypothesize that progestin treatment may decrease the 
longevity of the immune response to a heterologous IAV challenge as compared to placebo 
treatment (349, 350). Additionally, evaluating the effects of memory CD8+ T cells in not only a 
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secondary infection but tertiary infection may further shed a light on the role of progestins in 
long-term responses to IAV. 
Progestins do not affect CD4+ T cells in a heterologous IAV challenge 
Mice treated with progestins show no differences in total numbers of CD4+ T cells, and 
no differences in numbers of Th1, Th2 and Th17 cells following heterologous IAV challenge as 
compared to placebo. However, the role of Tregs during a heterologous IAV challenge has not 
yet been evaluated. Data show that memory Tregs regulate the CD8+ T cell response, and 
elimination of Tregs at the time of secondary IAV challenge enhances morbidity in mice (195). It 
is possible that fewer Tregs are generated during the primary IAV infection in progestin-treated 
mice due to progestins decreasing pulmonary inflammation. These lower numbers of Tregs may 
then contribute to the increased inflammation observed in the progestin-treated group during the 
heterologous IAV challenge. In a lethal model of IAV infection there are no differences in Tregs 
numbers or percentages between P4- and placebo-treated mice at 7dpi. However, it is possible 
that the intensity of the immune response in this lethal IAV model may mask any potential 
differences and that evaluating Tregs at later stages and following a sublethal infection may 
reveal potentially differences. Additionally, CD4+ T cells are important for generating TRM 
(206) and therefore evaluating the numbers of CD4+ T cells following the primary IAV infection 
may explain why progestin-treated mice have lower numbers of CD8+ TRM.  
The impact of progestins during IAV vaccination 
The studies from chapter 3, explore the role of progestins in memory responses to a live 
IAV virus which mimics a natural infection. However, IAV vaccination is widespread and occurs 
annually, and therefore evaluating the role of progestins in such a model would be of great value. 
To do so, the memory responses, both antibodies and memory T cells, as well as responses 
following a lethal IAV challenge would need to be evaluated in a vaccine model with mice 
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infected with an inactivated IAV and treated with progestins or placebo. I hypothesize that 
progestins would have a similar impact following vaccination, as the immune responses involved 
are similar to those against a live virus despite lower levels of  inflammation following infection 
with an inactivated virus (351). Inactivated viruses may generate lower response than a natural 
infection and it would be very interesting to evaluate whether the antibody responses against an 
inactivated virus vaccine would remain high enough to protect against a challenge with a lethal 
live IAV. 
The impact of hormonal contraceptives on infectious diseases 
As described in the introductory chapter, the role of progestins has mainly been evaluated 
in STIs infections and despite the widespread use of hormonal contraceptive very little research 
has been pursued to evaluate the role of hormonal contraceptives in viral diseases outside of the 
reproductive tract. Each viral infection has its characteristics but some of the cellular and 
molecular mechanisms are shared between viruses and the observations made in this dissertation 
for IAV have the potential to be expanded into other viral disease models. Very few of the studies 
examining the impact of progestins on infectious disease have focused on memory responses or 
responses to vaccination, and this is an area in particular that needs to be further expanded. This 
dissertation has evaluated the effects of progestins during IAV infection in a murine model, and 
this work needs to be translated into clinical research. Many epidemiological studies exist 
examining women on hormonal contraceptives and their risk of HIV acquisition or the effects of 
progestins on HIV disease progression (103-106). Human studies analyzing antibody responses to 
IAV need not only to acknowledge the sex of the subjects but their hormonal status should also 
be considered. Additional work in primary human pulmonary epithelial cells could also provide 
further insight on the role of progestins on these cells and their ability to promote repair.  
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Conclusion 
The overall impact of this dissertation resides in its novelty. Despite the growing use of 
hormones since the 1960s, very little work has been conducted on their role outside of the 
reproductive tract, and no studies prior to these have evaluated the impact of progestins on IAV 
infection, pathogenesis and memory responses. With this research, I hope to raise awareness to 
the potential impact of progestins on respiratory infections such as influenza which could 
possibly be expanded to any other respiratory infection or lung injury causing damage to the 
lungs. Along with their anti-inflammatory and reparative role, the impact of progestins on 
antibody and memory responses deserves to be further explored. With over 100 million women 
on hormonal contraceptives and worldwide annual influenza vaccinations, knowing the impact of 
these progestins on antibody production is essential.  
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Physiological Science department seminar at the Harvard T.H. Chan School of Public Health, 
Boston, MA, November 2016.  
2.   Hall OJ and Klein SL. Progesterone-based contraceptives alter immune responses and cross-
protection against influenza A viruses in female mice. Poster presentation at the 2016 Centers 
of Excellence for Influenza Research and Surveillance (CEIRS) Annual Meeting, Memphis, 
TN, July 2015 
3.   Hall OJ, Limjunyawong N, Vermillion MS, Robinson DP, Mitzner W, and Klein SL. 
Progesterone Protects Against Influenza by Upregulating Amphiregulin and Promoting Lung 
Repair and Recovery in Females. Oral presentation at the 2016 American Society of Virology 
(ASV) meeting, Blacksburg, VA, June 2016. 
4.   Hall OJ and Klein SL. Progesterone-based Contraceptives Alter Immune Responses and 
Cross-Protection Against Influenza A Viruses in Female Mice. Poster Presentation at the 
2016 Johns Hopkins Vaccine Day, Baltimore, MD, March 2016. Second place at poster 
competition.  
5.   Hall OJ, Limjunyawong N, Vermillion MS, Mitzner W, and Klein SL. The Effects of 
Progesterone on Pulmonary Repair During H1N1 Infection. Poster Presentation at the 2015 
Centers of Excellence for Influenza Research and Surveillance (CEIRS) Annual Meeting, 
Rochester, NY, July 2015  
6.   Vom Steeg LG, Hall OJ, Alam O, McFarland R, Zirkin B & Klein SL. Testosterone 
Regulates the Outcome of Influenza by Altering Adaptive Immune Responses in Male Mice. 
Poster presentation at the annual meeting of the American Society for Virology, Western 
Ontario, Canada, July 2015. 
7.   Hall OJ, Robinson DP, Klein SL. Progesterone Dampens Inflammation during Influenza A 
Virus Infection in Female Mice. Poster presentation at the 2015 Keystone Symposia on Viral 
Immunity, Breckenridge, CO, January 2015. 
8.   Glenn J, Smith M, Hall OJ, Klein SL, Whartenby K. CNS Autoimmunity Predisposes to 
Increased Influenza Morbidity. Poster presentation at the 2015 Keystone Symposia on Viral 
Immunity, Breckenridge, CO, January 2015. 
9.   Hall OJ, Robinson DP, Klein SL. What Your Mother Never Told You About the Pill. Invited 
oral Presentation at the annual Molecular Microbiology and Immunology retreat, Baltimore, 
MD, September 2014. 
10.  Hall OJ, Robinson DP, Klein SL. Progesterone Protects Female Mice Against Influenza A 
Virus Infection. Oral presentation at the 2014 American Society of Virology (ASV) meeting, 
Fort Collins, CO, June 2014 
11.  Hall OJ, Robinson DP, Klein SL. Progesterone Protects Female Mice Against Influenza A 
Virus Infection. Oral Presentation at the John’s Hopkins Women’s Health Research Group’s 
(WHRG) Symposium, Baltimore, MD, May 2014. 
12.  Hall OJ, Robinson DP, Klein SL. Progesterone Protects Female Mice Against Influenza A 
Virus Infection. Poster presentation at the 2014 Delta Omega Poster Competition, JHSPH, 
Baltimore, MD, February 2014 
13.  Ntranos A, Grishkan IV, Robinson DP, Hall OJ, Klein SL, Calabresi, PA, Gocke, AR. 
Fingolimod Inhibits Cytotoxic T Cells: A Novel Immunomodulatory Effect of the 
Unphosphorylated Compound. Oral presentation at the 2013 Americas Committee for 
Treatment and Research in Multiple Sclerosis (ACTRIMS) meeting, Orlando, FL, June 2013. 
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14.  Ntranos A, Grishkan IV, Robinson DP, Hall OJ, Klein SL, Calabresi, PA, Gocke, AR. 
Dissecting fingolimod’s action: a novel immunomodulatory effect of the unphosphorylated 
compound on cytotoxic T cell function. Oral presentation at the 2013 Annual American 
Association of Immunologists (AAI) meeting, Honolulu, HI, May 2013. 
15.  Hall OJ, Robinson DP, Klein SL.  The Pregnancy-Associated Hormones, Estriol and 
Progesterone, Have Differential Effects on the Outcome of Influenza A Virus Infection in 
C57BL/6 Female Mice. Oral presentation at the John’s Hopkins Women’s Health Research 
Group’s (WHRG) Symposium, Baltimore, MD, May 2013. 
16.  Hall OJ, Robinson DP, Klein SL.  The Pregnancy-Associated Hormones, Estriol and 
Progesterone, Have Differential Effects on the Outcome of Influenza A Virus Infection in 
C57BL/6 Female Mice. Poster presentation at the 2013 Organisation for the Study of Sex 
Differences (OSSD) meeting, Weehawken, NJ, April 2013.  
HONORS AND AWARDS 
•   American Society for Virology (ASV) Student Travel Grant. Received for an oral 
presentation at the 2016 ASV annual meeting, April 2016.  
•   Centers for Excellence in Influenza Research and Surveillance (CEIRS) Training 
Award. Received for training program at the Icahn School of Medicine Mount Sinai, NY 
with Dr. Florian Krammer, February 2016.  
•   Johns Hopkins School of Public Health (JHSPH) Student Conference Fund Award. 
Received for an     Oral Presentation at the 2014 ASV annual meeting, CO, June 2014.  
•   Oral Abstract Award received for an oral presentation at the Johns Hopkins Women’s 
Health Research Group’s Symposium, Baltimore, MD, May 2014. 
•   The Keerti V. Shah Fund Honorary Scholarship. Received for 2013-2014 at the Johns 
Hopkins School of Public Health in May 2013.  
•   Oral Abstract Award received for an oral presentation at the Johns Hopkins Women’s 
Health Research Group’s Symposium, Baltimore, MD, May 2013. 
•   The Carlton and Estelle Herman Award in Parasitology, Vector Biology and Animal-
Borne Diseases. Received for 2012-2013 at the Johns Hopkins School of Public Health in 
May 2012. 
AD HOC JOURNAL REVIEW 
Journal of Virology, FASEB, and PLoS One 
PROFESSIONAL MEMBERSHIPS 
•   American Society of Microbiology (ASM): 2012-current 
•   Organization for the Study of Sex Differences (OSSD): 2013-current 
•   American Society of Virology (ASV): 2014-current 
•   American Association of University Women (AAUW): 2012-2015 
•   Association for Women in Science (AWIS): 2014-current 
TEACHING EXPERIENCE 
Teaching assistant: Exam correction, review sessions and personal meeting with students for 
graduate-level courses by Dr. Alan Scott at the Johns Hopkins Bloomberg School of Public 
Health. 
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•   Principals of Immunology I and II, 2014 and 2015 
•   Topics in Immunology I and II, 2014 and 2015 
•   Immunology, Infection and Disease, 2014 and 2015 
 
Mentoring and training:  
•   Ross McFarland, Ph.D. rotation student, MMI (JHSPH), Term 3 2013 
•   Rebecca Yee, Ph.D. rotation student, MMI (JHSPH), Term 1 2013 
•   Landon vom Steeg, Ph.D. rotation student, MMI (JHSPH), Term 2/3 2013-14 
•   Ornob Alam, Master student, MMI (JHSPH), 2013-2015. The Effects of Elevated 
Testosterone on the Outcome of ma2009 H1N1 Influenza A Virus infection in Old Male 
Mice 
•   Phil Salvatore, Ph.D. rotation student, MMI (JHSPH), Term 4 2015 
•   Caroline Mejia-De Jesus, Summer Fellow in the James A. Ferguson Emerging Infectious 
Disease Fellowship program, Summer 2015 
•   Jamaiha Thomas, summer intern at the Johns Hopkins Summer Jobs Program, Summer 
2015 and 2016 
•   Kyla Britson, Ph.D. rotation student, Cellular and Molecular Medicine (JHMI), Term 1 
2015 
•   Angela Chen, Ph.D. rotation student, MMI (JHSPH), Term 3 2016 
•   Vanessa Phuong, summer student (undergraduate), Johns Hopkins University, Summer 
2016. 
RESEARCH METHODS AND SCIENTIFIC TRAINING  
Languages French: Native language 
   English: Native language 
   German: Fluent (speaking, reading, writing. 9 years of study) 
Cell culture: Cell harvesting from tissues and blood isolated from mice and humans, isolation of 
specific cell populations, cell line cultures, in vitro lymphocyte stimulation with pathogens, APC 
co-culture, in vitro cell differentiation, and virus titration (TCID50). Isolation and differentiation 
of mouse tracheal epithelial cells.  
Cell biology: Fluorescence-activated cell sorting (FACS, Calibur and LSRII), extra/intracellular 
cytokine staining, FLOWJO analysis, proliferation assays (3H-thymidine and CFSE), ELISA, 
ELISPOT, Luminex assays, transfection, virus neutralisation assay, Immunohistochemistry and 
immunofluorescence microscopy. Assay development and troubleshooting. 
Molecular biology: RNA extraction, cDNA synthesis, RT-PCR, Influenza, HIV and adenovirus 
manipulation, virus purification and culture, magnetic-activated cell sorting. 
Protein analysis: 2D-PAGE, HPLC, peptide synthesis (FMOC), and Mass spectrometry. 
Animal work:  Rodent handling (rats and mice), survival surgery in mice (gonadectomy), 
subcutaneous implantation of hormone pellets, body weight and temperature monitoring, 
injections, intranasal infection, dissection, lung fixation, blood collection, behavioural 
assessments and knock-out breeding techniques. 
Clinical research: Knowledge of ethics, study designing, and basic nursing skills (blood 
collection, injections and phlebotomy).  
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Computer skills: Excel, PowerPoint, Word, Windows, Mac, FlowJo, GraphPad Prism, Systat, 
SigmaPlot, Adobe Illustrator.  
STUDENT ORGANIZATIONS 
JHSPH Student Assembly – Member at large: 2015-2016 
JHSPH Student Assembly – Department Representative: 2014-2015 
MMI Department (JHSPH) – Student Group Member: 2011-2016 
